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LIPOCALIN 2 PROMOTES THE ESTABLISHMENT OF A PRO-
TUMORIGENIC MICROENVIRONMENT IN PANCREATIC CANCER  
Sobeyda B. Gomez-Chou, B.S.  
Advisory Professor: Craig D. Logsdon 
        Pancreatic ductal adenocarcinoma (PDAC) is a disease characterized 
by a dismal prognosis with a 5-year survival rate of 7%. A unique hallmark 
of this disease is an abundant desmoplastic reaction that can account for up 
to 90% of the solid tumor volume. Key components of the PDAC stroma 
include the extracellular matrix (ECM) rich in collagen type I and III, 
activated pancreatic stellate cells (PSCs) and inflammatory cells such as 
neutrophils and macrophages. The main line of evidence has suggested a 
pro-tumorigenic role for the PDAC stroma as it has been shown to help 
enhance tumor growth, invasive potential and drug resistance. Recent 
reports however, have challenged these findings and shown that the stroma 
offered protection from tumor growth. Given the extensive presence of 
stroma and its presumed roles in PDAC, characterization of the function of 
molecules that can alter stromal composition is warranted. LCN2 is a 
molecule that has been confirmed to be differentially expressed in PDAC. 
Attempts to investigate its biological function in PDAC have unfortunately led to 
conflicting results. In this study, we examined the effect of LCN2 depletion on 
tumor growth in a syngeneic orthotopic model of PDAC. We report that LCN2 
depletion delayed tumor growth, decreased changes in stromal composition, and 
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diminished inflammatory cell infiltration leading to increased survival. In addition, we 
examined the role of LCN2 and its specific receptor SLC22A17 in human PSCs. We 
revealed for the first time that hPSCs don’t produce LCN2, but do express LCN2 
receptors. Moreover, ectopic LCN2 promoted hPSCs to produce inflammatory 
factors in a receptor-mediated manner. Finally, because LCN2 is involved in iron 
transport, we showed that LCN2’s effects on hPSCs were also mediated by changes 
in iron levels. Overall, our results suggest a model for LCN2 function in the 
regulation of the tumor microenvironment and shown its ability to promote tumor 
growth in PDAC.  
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Pancreatic Cancer 
        Human Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth leading cause 
of cancer-related deaths in the United States (Fokas et al., 2015). Projected to 
become the second leading cause of cancer-related deaths by the year 2020, PDAC 
will only fall behind lung cancer (Rahib et al., 2014). Early stage PDAC is usually 
asymptomatic and the majority of cases are diagnosed when the disease is 
advanced and has metastasized to distant areas. According to the National Cancer 
Institute, nine percent of PDAC patients are diagnosed when the disease is localized 
to the pancreas while over fifty percent of patients are diagnosed when the disease 
has already spread to other organs.  Because the five-year relative survival rate for 
patients with distant disease is just over two percent, the majority of patients 
diagnosed with PDAC have a very dismal possibility for surviving this malignancy.   
Pancreatic pre-invasive lesions and PDAC development 
        Multiple observations have suggested that the development of non-invasive 
pancreatic intraepithelial neoplasia (PanIN) can be attributed to acinar cell to ductal 
cell metaplasia (Brune et al., 2006; Zhu et al., 2007). While other non-invasive 
pancreatic neoplasia have been found including mucinous cystic neoplasm (MCN) 
and intraductal papillary mucinous neoplasm (IPMN), PanINs are more common 
(Hruban et al., 2008). PanIN lesions appear to be present in non-cancerous 
pancreas and their prevalence increases with age (Schwartz and Henson, 2007). 
However, PanIN lesions alone do not have a high potential to develop to invasive 
cancer (Terhune et al., 1998). Further, three stages of PanIN lesions are found in 
the pancreas named PanIN-1, PanIN-2 and PanIN-3. PanIN-1 lesions contain 
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columnar epithelial cells with round nuclei. PanIN-2 lesions exhibit more extensive 
nuclear morphological changes, and PanIN-3 lesions form papillae and cribriform 
structures with more complex dysplasia (Hruban et al., 2008).  
        Genetic alterations have been reported as early as in PanIN-1 lesions. Mainly, 
an oncogenic point mutation in codon 12 of the Kras oncogene is found in over 95% 
of PDAC cases and has been detected in PanIN-1 lesions (Gharibi et al., 2016). The 
excessive activation of this oncogene via its mutation and stimulation by exogenous 
signals can lead to cell proliferation, differentiation and survival. Other alterations 
including the inactivation or deletion of the tumor suppressors CDKN2A (p16/Ink4A), 
TP53 and Smad4 are observed in the progression from PanIN-2/3 lesions to PDAC 
(Hruban et al., 2008). Despite the early accumulation of genetic alterations, a study 
has proposed that the progression from localized tumor to metastatic disease could 
occur over a decade (Yachida et al., 2010). This finding indicates a window of 
opportunity for the early detection of PDAC and for medical intervention before the 
disease metastasizes (Figure 1).  
  
4 
 
Figure 1. PDAC development and the tumor microenvironment. PDAC develops 
over a long period of time beginning with the formation of pancreatic pre-invasive 
neoplastic lesions called PanINs. Beginning in early PanIN-1, genetic mutations 
such as in the Kras gene are observed. Progression of PanIN-1 lesions to PanIN-2 
and 3 occurs with additional genetic mutations, dysplasia and the accumulation of 
stromal components including the ECM, inflammatory cells, cancer associated 
fibroblasts and pancreatic stellate cells. An extensive stroma is a hallmark of PDAC. 
The time it takes to get from tumorigenesis onset to invasive PDAC suggests a 
potential window for medical intervention. (Figure 1 taken with permission from 
Fokas, E., O'Neill, E., Gordon-Weeks, A., Mukherjee, S., McKenna, W.G., and 
Muschel, R.J.Pancreatic ductal adenocarcinoma: From genetics to biology to 
radiobiology to oncoimmunology and all the way back to the clinic, Biochimica et 
Biophysica Acta (BBA) - Reviews on Cancer, Volume 1855, Issue 1, January 2015, 
Pages 61-82. License ID: 3840020158964). 
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 Pancreatic stroma 
        PDAC is a unique solid tumor in which an extensive desmoplastic reaction can 
constitute up to 90% of the tumor volume (Gharibi et al., 2016). This PDAC stroma is 
a heterogeneous and dynamic compartment implicated in the process of tumor 
formation, progression, invasion and metastasis (Chu et al., 2007). It contains 
various acellular and cellular components including the extracellular matrix (ECM), 
matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs), cytokines and 
growth factors as well as stromal cells such as fibroblasts, pancreatic stellate cells 
(PSCs) and inflammatory cells (Feig et al., 2012). The ECM is comprised of fibrous 
proteins including collagens I and III, fibronectin and laminin as well as other 
proteins including glycoproteins, glycosaminoglycans and proteoglycans. Alterations 
in the composition of the ECM has been shown to regulate tumor invasion and 
metastasis (Hidalgo, 2010). MMPs are a family of proteolytic enzymes produced by 
tumor and stromal cells that degrade the ECM. Their expression can be induced by 
several growth factors, hormones and cytokines (Stamenkovic, 2000). Moreover, 
certain MMPs have the ability to activate other MMPs. For instance, MMP-3 has 
been shown to be able to activate the mature MMP-1, MMP-7 and MMP-9. MMPs 
can be further classified into six different types based on the substrates they bind 
such as collagens, gelatins, fibronectin and elastin among others. In pancreatic 
cancer, MMPs have been found to be upregulated and to correlate with malignancy 
(Bloomston et al., 2002). Specifically, the expression of MMP-1, MMP-3 and MMP-9, 
among other MMPs, has been correlated with degree of desmoplasia, tumor extent, 
nodal status and with survival in pancreatic cancer.  
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        A milieu of cytokines and growth factors including TNF-α, TGF- α, TGF-β, 
Interleukins 1, 6, 8, 10, 17, 22 and VEGF among others have been identified in the 
PDAC stroma and are implicated in tumor initiation, progression and metastasis 
(Delitto et al., 2015). These factors can be produced by inflamed acinar cells, cancer 
cells, inflammatory cells and by PSCs. Human pancreatic stellate cells (hPSCs) 
have been extensively studied and are known to actively contribute to the 
establishment of the pancreatic tumor microenvironment. In fact, hPSCs are key 
producers of ECM components including collagens I/III and fibronectin, growth 
factors including TNF-α, TGF-β, VEGF and stromal derived factor 1 (SDF-1), MMPs, 
TIMPs, cytokines and chemokines (Duner et al., 2010; Mace et al., 2013; Omary et 
al., 2007).Quiescent hPSCs are present in the normal pancreas but they become 
activated upon acute and chronic inflammatory stimuli. Activated hPSCs are 
characterized by morphologic changes, expression of the α-smooth muscle actin (α-
SMA), increased ECM deposition and increased proliferation (Omary et al., 2007). 
Moreover, hPSCs have been shown to be activated by platelet derived growth factor 
(PDGF), TNF-α, TGF-β, fibroblast growth factor (FGF) and Interleukins 1β, 6, 8 that 
are released by cancer cells and leukocytes that have been recruited to areas of 
injury (Duner et al., 2010; Jaster, 2004; Omary et al., 2007). Thus, a crucial crosstalk 
between cancer cells, immune cells and hPSCs occurs in the PDAC stroma.  
        Consequently, many studies have examined the role of hPSCs and the stroma 
on PDAC development and growth. Several studies have shown that the co-culture 
of hPSCs or conditioned media from hPSCs with PDAC cells increases the 
proliferation, migration and invasion potential of cancer cells in vitro. Moreover, the 
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co-injection of hPSCs with PDAC cells has been shown to enhance tumor growth 
and metastasis (Erkan et al., 2012; Hwang et al., 2008; Vonlaufen et al., 2008). 
Numerous studies have also demonstrated the role of the stroma in promoting tumor 
growth and progression (Bachem et al., 2005; Duner et al., 2010; Korc, 2007; 
Mahadevan and Von Hoff, 2007). Interestingly a few recent reports have suggested 
a protective role for the stroma in tumor development and metastasis using genetic 
models that eliminate stellate cells during cancer initiation (Ozdemir et al., 2014; 
Rhim et al., 2014). These reports indicate the need for further studies to clarity the 
function of stromal components and their effect of PDAC.   
Pancreatic cancer and inflammation 
        Inflammation of the pancreas, referred to as pancreatitis, has been suggested 
by many studies to be a risk factor for PDAC development (Lowenfels et al., 1993). 
Interestingly, the stromal components observed in pancreatitis are similar to those 
observed in PDAC (Delitto et al., 2015; Erkan et al., 2012; Lowenfels et al., 1993). 
Specifically, the activation of hPSCs, deposition of ECM components, expression of 
cytokines and growth factors and inflammatory cell infiltration is observed in 
pancreatitis (Guerra et al., 2007). Strong upregulation of the inflammatory mediators 
TNF-α, SDF-1, IL-1β, IL-6, IL-8, monocyte chemoattractant protein 1 (MCP-1), 
intercellular adhesion molecule 1 (ICAM-1) and the complement component C5a has 
been implicated in the development of pancreatitis and progression to PDAC 
(Gukovsky et al., 2013; Matsuo et al., 2012). In addition to the upregulated presence 
of cytokines and chemokines, the presence of inflammatory cells also change in the 
progression from neoplastic lesions to PDAC. For instance, tumor associated 
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macrophages (TAMs) and myeloid derived suppressor cells (MDSCs) infiltrate the 
stroma early on during low grade lesions and persist through invasive PDAC 
development (Clark et al., 2007). These inflammatory cells have been shown to 
suppress the host immune system and may promote disease progression. Further, it 
has been suggested that the migration of these cells is mediated by pro-
inflammatory cytokines and chemokines secreted by hPSCs including IL-6, IL-8 and 
MCP-1 among others.   
        Because PDAC is a very deadly disease and early detection is critical for 
medical intervention, many groups have attempted to dissect the differences in the 
inflammatory response seen in pancreatitis versus PDAC. Several analyses of 
human serum have shown that IL-6, IL-8 and TNF-α are significantly overexpressed 
in PDAC compared to benign patients and patients with pancreatitis (Blogowski et 
al., 2014; Ebrahimi et al., 2004). Similarly, a member of the lipocalin family, Lipocalin 
2 (LCN2), has been found to be significantly upregulated in PDAC tissue and serum. 
Studies have shown weak to no LCN2 expression in normal tissue and pancreatitis 
samples compared to PDAC (Devireddy et al., 2001; Moniaux et al., 2008). Thus, 
the differential expression of LCN2 in PDAC suggests its use as a potential maker of 
this disease.  
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The Lipocalin family 
        The lipocalins are a large family of small proteins present in both prokaryotes 
and eukaryotes (Goetz et al., 2000). They are capable of binding, storing and 
transporting a large range of small hydrophobic molecules including vitamins and 
steroid hormones (Chakraborty et al., 2012; Du et al., 2015). Moreover, they have 
been implicated in a variety of different functions including transport of retinols and 
pheromones and synthesis of prostaglandins and immune cell recruitment among 
others (Flower, 1996; Flower et al., 2000). Many studies have performed structural 
analysis of several lipocalin family members to better understand their function. It 
has been found that this family of proteins share a varied amount of sequence 
conservation with some cases indicating sequence identity as low as twenty percent 
(Chakraborty et al., 2012; Flower, 1996). Nevertheless, lipocalins share a common 
secondary and tertiary structural feature named the lipocalin fold (Flower, 1994; 
Flower et al., 1991). This fold forms a cavity that aids ligand binding and the 
difference in amino acids that form this fold gives rise to the diverse amount of 
ligands bound by lipocalins (Du et al., 2015; Ganfornina et al., 2000; Schiefner and 
Skerra, 2015).   
Identification and expression of Lipocalin 2 
        Lipocalin 2 (LCN2) is a molecule that has developed considerable research 
interest since its discovery decades ago. It was first identified as a small 
superinducible protein during the growth factor treatment of murine fibroblasts (Davis 
et al., 1991; Nilsen-Hamilton et al., 1982). Ever since, an extensive number of 
studies have examined the expression of this molecule in different species and 
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aimed to elucidate its function. Interestingly, results from such studies have led to a 
complicated and varied nomenclature for this specific lipocalin member. For 
example, Lipocalin 2 is also known as neutrophil glucosaminidase-associated 
lipocalin (NGAL), 24p3, migration stimulating factor inhibitor (MSFI), SIP24, Ch21, 
α1-microglobulin related protein, uterocalin and siderocalin (Chakraborty et al., 2012; 
Chan et al., 1988; Descalzi Cancedda et al., 1988; Hraba-Renevey et al., 1989). 
Thus, in order to get a thorough understanding on past and present LCN2 
publications it is necessary to search under all of these names that have been given 
to this lipocalin member.  
        Human LCN2 was first found and isolated in a complex with the matrix 
metalloproteinase 9 (MMP-9) in neutrophils (Triebel et al., 1992). Following studies 
revealed that LCN2 was a secreted protein capable of being detected in human 
serum in quantities ranging from 40-109 ng/mL (Kjeldsen et al., 1993). Additional 
research revealed LCN2 expression in various human tissues including in breast, 
bone marrow, kidney, liver, trachea, lung, salivary glands, prostate, adipocytes and 
macrophages (Cowland and Borregaard, 1997; Cowland et al., 2003; Moreno-
Navarrete et al., 2010). Further, LCN2 is expressed and upregulated in a variety of 
benign diseases. For instance, LCN2 is reported to be upregulated in inflammatory 
diseases including periodontitis, myocardidis, HIV and ulcerative colitis; in metabolic 
diseases including in diabetic and obese patients; in renal diseases including in 
kidney injury and chronic kidney disease (Landro et al., 2008; Sahinarslan et al., 
2011; Van Dyke et al., 1985; Viau et al., 2010; Wang et al., 2007).  
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LCN2’s role in iron transport via siderophores and specific receptors 
        Upon its discovery, several groups began to elucidate the three-dimensional 
structure of LCN2. Nuclear magnetic resonance (NMR) analysis revealed that the 
ligand binding cavity, or lipocalin fold, of LCN2 was significantly polar. Subsequently, 
one group used the results from LCN2 crystallography to identify a ligand for LCN2 
(Goetz et al., 2002). A bacterial chromophore containing iron was found to bind 
tightly and specifically to LCN2. Further analysis revealed that this ligand was ferric 
enterobactin, a siderophore. Siderophores are proteins with high affinity to ferric iron 
(Fe3+) that make iron available to bacteria which is essential for their survival 
(Neilands, 1995). Moreover, it was found that LCN2 binds iron only in complex with a 
siderophore and not directly. Subsequent studies have also revealed the presence 
of mammalian siderophores called catechols that are able to bind LCN2 in the 
human body (Bao et al., 2010). These metabolites can be derived from plant 
sources and can also be synthesized in the body from dietary proteins. Specifically, 
the mammalian siderophore 2,5-dihydroxy benzoic acid (2,5-DHBA) was shown to 
bind LCN2 in the pro-B murine cell line FL5.12 (Devireddy et al., 2010). 
        Through its ability to bind iron-laden siderophores, LCN2 has been shown to 
regulate iron levels in mammalian cells. LCN2 was also first implicated to have a role 
in promoting cell death (Devireddy et al., 2001). One group identified a cell-surface 
receptor that allowed for LCN2-mediated iron uptake in FL5.12 cells (Devireddy et 
al., 2005). Two cell-surface proteins have been demonstrated to bind LCN2: solute 
carrier family 22 member 17 (SLC22A17) and low density lipoprotein receptor 
related protein (LRP2 or megalin) (Chakraborty et al., 2012). Both SLC22A17 and 
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LRP2 have been reported to bind and mediate the cellular uptake of LCN2 (Cabedo 
Martinez et al., 2016; Devireddy et al., 2005; Fang et al., 2007). While SLC22A17 
has been shown to bind specifically to LCN2, LRP2 also binds numerous structurally 
unrelated molecules including aprotinin, vitamin D3 and lactoferrine (Hvidberg et al., 
2005; Miyamoto et al., 2011a). While there is a limited amount of research published 
for SLC22A17, recent reports have indicated that its expression is correlated with 
malignancy. For instance, overexpression of both LCN2 and SLC22A17 has been 
associated with a worse prognosis in gliomas, hepatocellular and endometrial 
cancer (Liu et al., 2011; Miyamoto et al., 2011a; Zhang et al., 2012).   
LCN2 and inflammation 
        Tight regulation of the immune system is essential for the body’s defense 
against foreign pathogens and to prevent autoimmune malignancies. A myriad of 
molecules are involved in the complex activation and regulation of the inflammatory 
response. LCN2 has been implicated to function in a pro-inflammatory fashion and it 
is often times referred to as a cytokine. In a study using LCN2 deficient mice, it was 
found that macrophages, fibroblasts and endothelial cells produced and secreted 
high levels of LCN2 upon bacterial infection (Flo et al., 2004). In addition, a mouse 
model of allogenic cardiac transplant showed that LCN2 deficient mice exhibited 
significantly reduced levels of infiltrating neutrophils compared to control animals 
(Aigner et al., 2007). Other in vivo infection studies have also shown that LCN2 aids 
in the recruitment of neutrophils and is important in the activation and migration of 
these immune cells to sites of inflammation (Bachman et al., 2009; Schroll et al., 
2012; Wu et al., 2010). 
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        The fact that LCN2 expression is rapidly induced upon infection in different 
species including in humans, mice, and rats clearly implicates LCN2 in the immune 
response. The intricate relationship between LCN2, inflammatory molecules and its 
regulation has been examined by many (Chakraborty et al., 2012). In vitro and in 
vivo studies have shown that LCN2 expression can be induced by various pro-
inflammatory cytokines and growth factors. Interleukins 1B, 1α, 6, 17, 22, tissue 
necrosis factor α (TNF-α), nuclear factor κB (NF-κB), granulocyte monocyte colony 
stimulating  factor (GMCSF), transforming growth factor a (TGF-α) and insulin like 
growth factor 1 (IGF-1) have been previously shown to induce LCN2 expression 
(Aujla et al., 2008; Cowland et al., 2006; Cowland et al., 2003; Fujino et al., 2006; 
Landro et al., 2008; Raffatellu et al., 2009; Sorensen et al., 2003). The LCN2 
promoter contains a binding site for NF-κB resulting in the positive regulation of 
LCN2 (Iannetti et al., 2008; Shen et al., 2006). Of note, the ability of all these factors 
to upregulate LNC2 expression has been found to be cell or tissue dependent 
indicating the need to study their effect on LCN2 in tissues of interest.          
LCN2 in cancer  
        In addition to being involved in inflammation, LCN2 is also upregulated in 
cancer. Studies have shown that LCN2 expression is abnormally high in thyroid, 
ovarian, breast, endometrial, colorectal, rectal, gastric, hepatocellular, oesophageal, 
lung, gliomas, chronic myeloid leukemia and in pancreas cancer (Bousserouel et al., 
2010; Cho and Kim, 2009; El-Serag and Rudolph, 2007; Furutani et al., 1998; Santin 
et al., 2004; Villalva et al., 2008; Wang et al., 2010).  A significant number of studies 
have also described the potential involvement of LCN2 in the biology of these 
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cancers. In breast cancer, excessive LCN2 expression has been shown to enhance 
tumor growth, migration, invasion and metastasis by inducing cell growth and 
promoting epithelial to mensenchymal transformation (Fernandez et al., 2005; Shi et 
al., 2008; Yang et al., 2009). LCN2 knockdown has shown to prevent thyroid cancer 
cell growth and tumor formation (Iannetti et al., 2008). LCN2 expressing endometrial 
tumor cells exhibited increased proliferation rates and invasive abilities (Miyamoto et 
al., 2011b). Lung cancer cells demonstrated upregulated LCN2 expression in 
response to apoptotic stimuli leading to increased survival (Tong et al., 2005). In 
colorectal cancer, LCN2 overexpression promoted cancer cell invasion potential and 
enhanced tumorigenesis in a xenograft model (Sun et al., 2011).  
        Some of these tumors, including in kidney and breast,  have been shown to 
raise the levels of LCN2 in blood, urine and other biological fluids in addition to the 
primary tissue (Lippi et al., 2014). In addition, for many of these cancers, LCN2 
expression has been shown to have a positive correlation with degree of 
differentiation, tumor aggressiveness and decreased survival (Lippi et al., 2014). In 
renal cell carcinoma, serum and urine LCN2 levels have been associated with 
mortality and shorter progression-free survival (Morrissey et al., 2011; Perrin et al., 
2011). Higher plasma LCN2 levels have been found in patients with colorectal 
cancer and it has been associated with disease progression, stage, metastasis and 
mortality (Marti et al., 2013; Zhang et al., 2009). In gastric cancer, high serum LCN2 
levels are associated with metastasis, invasion and mortality (Wang et al., 2010). 
LCN2 expression is associated with stage, invasion and tumor recurrence in hepatic 
cancer (Zhang et al., 2012). In breast cancer, LCN2 expression in tissue and serum 
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has been associated with tumor grade, estrogen and progesterone receptor status 
and with decreased disease-free survival (Bauer et al., 2008; Wenners et al., 2012). 
LCN2 expression is also associated with tumor aggressiveness, recurrence and 
mortality in endometrial cancer (Mannelqvist et al., 2012). The results from all these 
studies suggest the potential use of LCN2 as a diagnostic and prognostic marker in 
various cancerous malignancies. 
LCN2 in PDAC 
        In a study designed to identify unique proteins produced by pancreatic ductal 
adenocarcinoma cells (PDAC), LCN2 was found to be differentially secreted by 
cancerous cells compared to normal tissue (Furutani et al., 1998). Other studies 
confirmed the upregulation of LCN2 in pancreatic cancer cells and in tumor tissue 
indicating its possible use as a PDAC marker (Han et al., 2002). It was further 
revealed that certain PDAC cell lines exhibited LCN2 upregulation approximately 
thirty-fold while other PDAC cells didn’t express much higher levels than normal cells 
(Chakraborty et al., 2012). Another study examined LCN2 expression in the early 
stages of pancreatic cancer. LCN2 was observed to be differentially expressed 
beginning in early PanIN lesions which was positively correlated with the 
progression of the disease (Moniaux et al., 2008). More specifically, 
immunohistochemistry identified a very strong LCN2 staining pattern in PanIN-1, 
PanIN-2, PanIN-3 lesions and in invasive adenocarcinoma compared to pancreatitis 
and normal adjacent tissue (Figure 2). Prior reports have also demonstrated that 
LCN2 is highly upregulated in the serum of PDAC patients compared to chronic 
pancreatitis and normal healthy individuals (Kaur et al., 2013; Kaur et al., 
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2014).These studies have thus indicated that LCN2 could be used as a potential 
marker for the detection of PDAC in conjunction with other specific PDAC 
biomarkers. 
        
Figure 2. Immunohistochemical analysis of the progressive expression of 
LCN2 in PDAC development. LCN2 expression is weak to non-existent in normal 
pancreas tissue. Upon inflammatory injury, LCN2 expression is moderately 
upregulated in pancreatitis. Its expression correlated with the progression of pre-
invasive lesions PanIN-1, 2, 3 and PDAC. (Figure taken with permission from 
Moniaux, N., Chakraborty, S., Yalniz, M., Gonzalez, J., Shostrom, V.K., Standop, J., 
Lele, S.M., Ouellette, M., Pour, P.M., Sasson, A.R., Brand, R.E., Hollingsworth, 
M.A., Jain, M., and Batra, S.K. Early diagnosis of pancreatic cancer: neutrophil 
gelatinase-associated lipocalin as a marker of pancreatic intraepithelial 
neoplasia. British Journal of Cancer. 2008;98(9):1540-1547. License ID: 
3838480336765)     
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 Further studies to identify a potential mechanism by which LCN2 may affect PDAC 
have so far been inconclusive. Two studies, one in 2008 and one in 2012, that made 
use of PDAC cell lines and xenograft mouse models to study LCN2, reported 
conflicting results. In the earlier study, LCN2 overexpression in two PDAC cell lines 
with low endogenous LCN2 levels significantly blocked the adhesion and invasion 
potential of these cells by decreasing focal adhesion kinase (FAK) phosphorylation 
and reduced the production of the vascular endothelial growth factor (VEGF) (Tong et 
al., 2008). In the same study, in vivo analysis demonstrated that the overexpression 
of LCN2 in a PDAC cell line implanted in an orthotopic nude mouse reduced tumor 
volume and metastasis. On the other hand, the later study reported that LCN2 
depletion in two PDAC cell lines with high endogenous LCN2 levels significantly 
reduced adhesion, and increased invasion and tumor growth in subcutaneous SCID 
mice. Moreover, LCN2 was shown to promote VEGF expression which contributed to 
enhanced tumor vascularity (Leung et al., 2012). Thus, results from these studies 
have offered contradictory findings in the search for understanding LCN2’s role in 
PDAC.  
Hypothesis 
        Given the amounting evidence linking LCN2 to inflammation and PDAC and the 
lack of a clear biological role for LCN2 in this disease, we investigated if LCN2 
depletion promoted tumor growth in a syngeneic orthotopic mouse model of PDAC. 
Previous studies for LCN2 in PDAC have made use of xenograft mouse models with 
compromised immune systems. Because of the important role inflammation plays in 
the development of PDAC and the fact that LCN2 may function as a cytokine, we 
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decided that studies in a syngeneic orthotopic model would more appropriately 
demonstrate tumor-host interactions. We hypothesized that LCN2 depletion would 
lead to decreased tumor growth along with a reduced immune response. To test this 
hypothesis, we implanted murine PDAC cells that naturally expressLCN2 in the 
pancreas of wild-type mice with genetic deletion of LCN2 expression. We then 
monitored tumor growth and assessed survival. 
        To obtain a better understanding of the role of LCN2 in the PDAC 
microenvironment, we examined the effect of LCN2 on hPSCs.  While prior reports 
have already indicated the expression of LCN2 in PDAC cells,  LCN2 expression 
and effects on hPSCs has not been reported. We hypothesized that LCN2, acting as 
a potential cytokine, could induce the synthesis and secretion of pro-inflammatory 
mediators by hPSCs. Many studies have previously shown the ability of cytokines to 
function in a paracrine and autocrine fashion in the crosstalk between PDAC cells 
and hPSCs. Thus, we tested our hypothesis by treating hPSCs with LCN2, knocking 
down its specific receptor SLC22A27 and assessing if iron was involved in LCN2-
mediated effects. Together, this work addressed a mechanism and biological 
function by which LCN2 could promote the establishment of a pro-tumorigenic 
microenvironment in PDAC. 
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Cell Culture 
        All cell lines were cultured at 37 °C with 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) with 4.5 g/L glucose and L-glutamine supplemented with 
10% v/v fetal bovine serum (FBS)  were routinely tested for mycoplasma, and found 
to be negative. BXPC3, HPAC, CAPAN2, MIAPACA2 and MPANC96 were obtained 
from American Type Culture Collection (ATCC). CAPAN1 cells were kindly provided 
by Drs. Collisson, Gray and McMahon (University of California and Lawrence 
Livermore Laboratory, San Francisco). Human pancreatic ductal epithelial (HPDEs) 
and Human pancreatic nestin-expressing cells (HPNEs) were obtained from Dr. 
Timothy Eberlein (St. Louis, MO) and Dr. Tsao (Ontario Cancer Institute, Toronto, 
ON, Canada) (Campbell et al., 2007; Lee et al., 2003; Qian et al., 2005). Human 
pancreatic stellate cells (HPSCs) were obtained from patient tissue by the outgrowth 
method and immortalized using lentiviral vectors with human telomerase (hTERT) or 
SV40 large T antigen (TAg) (Hwang et al., 2008). KPC cells were derived from a 
pancreatic tumor from a PDX-1-Cre, LSL-KrasG12D, LSL-Trp53-/- (KPC) genetically 
engineered mouse model (GEMM) and transfected with enhanced firefly luciferase 
(Ma et al., 2013; Olive et al., 2009). 
Orthotopic model of pancreatic cancer 
        All animal experiments were reviewed and approved by the MD Anderson 
Institutional Animal Care and Use Committee. All animals used were C57BL/6 strain 
mice. LCN2 knockout (LCN2-/-) animals were kindly provided by Dr. Ralph 
Arlinghaus (MD Anderson Cancer Center) (Flo et al., 2004). KPC-LUC cells in single 
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suspension were prepared and mixed in HBSS and 20% Matrigel (BD Biosciences, 
Bedford, MA, USA) All surgeries were performed in a sterile environment under 
anesthesia. After 1-cm longitudinal skin incision made on the left upper axillary 
region of the abdomen of the mouse, the peritoneum was opened. The pancreatic 
capsule was cut and a suspension of 0.5x106 KPC-LUC cells in a total volume of 50 
µL was carefully implanted via a 27 gauge needle into the pancreas. The pancreas 
was then put back into the abdominal cavity gently and the surgical opening was 
closed. Tumor growth was visualized by injecting mice with D-Luciferin (150 
µg/mouse; Caliper Life Sciences) and measuring bioluminescence using the IVIS 
imaging system (Caliper Life Sciences) (Ma et al., 2013). All animals (LCN2+/+ n=20 
and LCN2-/- n=17) were imaged on a weekly basis until sacrifice was required. 
Immunohistochemistry 
        Pancreatic tissue from each animal was fixed with 10% formaldehyde in 
phosphate-buffered saline overnight. After incubation, samples were embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Further 
immunohistochemical staining was performed in pancreatic paraffin sections using 
the antibodies and conditions listed in Table 1. Briefly, after deparaffinization using 
the standard procedure of two washes with Xylene, 100% Ethanol, 95% Ethanol, 
and one wash of 80% Ethanol, antigen retrieval (1 x DAKO target retrieval solution, 
DAKO, Carpinetria, CA) was performed in a steamer for 20 minutes at 98°C. Then, 
endogenous blocking with H2O2 was done followed by washing and blocking, and 
primary antibodies were applied overnight (4°C). After washing with PBS and PBS 
containing 0.05% Tween20, sections were incubated with the appropriate secondary 
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antibodies. Positive labeling was detected by exposing sections to DAB+Substrate 
system (DAKO) and finally counterstaining with hematoxylin solution.  
        Collagen deposition was detected using a Picro-Sirius Red Stain Kit (Abcam, 
ab150681) in paraffin embedded pancreatic tissue. Briefly, the sections were 
deparaffinized and hydrated in distilled water. Adequate Picro-Sirius Red Solution 
was applied to tissue sections and incubated for 60 minutes. Next, the sections were 
rinsed quickly in 2 changes of Acetic Acid Solution followed by rinsing in absolute 
alcohol.  
Primary antibody Source Dilution Secondary antibody, 
source 
Rat anti F4/80 e-Bioscience, 14-
4801 
1:250  Vectastatin Elite ABC Kit (rat 
IgG), Vector Laboratories, 
PK-6104 
Rabbit Anti-α-SMA  Abcam, ab5694 1:200  Vectastatin Elite ABC Kit 
(rabbit IgG), Vector 
Laboratories, PK-6101 
Biotin rat-anti 
CD45  
BD Pharmingen, 
553078 
1:500  NA 
Rabbit anti Ki-67 Sigma Aldrich, 
AB9260 
1:200 Vectastatin Elite ABC Kit 
(rabbit IgG), Vector 
Laboratories, PK-6101 
 
Table 1: List of antibodies used for immunohistochemical staining of mouse 
pancreas 
RNA isolation and quantitative RT-PCR 
        RNA was isolated from cells and mouse pancreas using TRIzol® Reagent (Life 
Technologies). Briefly, cells were scrapped after adding TRIzol® Reagent while 
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snap-frozen pancreas tissue was homogenized for twenty seconds. Chloroform was 
added to each sample and centrifuged at 12,000 g for fifteen minutes. The upper 
aqueous phase containing RNA was collected and washed with 100% isopropanol 
and then with 75% ethanol. RNA was resuspended in RNase-free water and RNA 
concentration was measured using a NANODROP 1000 spectrophotometer 
(Thermo Scientific). cDNA was prepared by reverse transcription using the Verso 
cDNA Synthesis Kit (Thermo Scientific). Gene expression was determined by 
quantitative PCR using the primer sequences listed in Table 2.  
Gene Forward Sequence Reverse Sequence 
hLCN2 GAAGTGTGACTACTGGATCAGGA 
 
ACCACTCGGACGAGGTAACT 
 
hSLC22A17 GCTGCCTGCCGGTGCTCTTCGTG GCTGGCGGCGCTGGCTGCTA 
hLRP2 TCATGGATGGCAGCAACCGTAAAG AAACCGAGAGTCAACCCAGTAAAC 
mLCN2 TGGCCCTGAGTGTCATGTG 
 
CTCTTGTAGCTCATAGATGGTGC 
 
mSLC22A17 TTTGGCCGTCGTGGGATTG 
 
GGCGCATCAGGTAGACACC 
 
mLRP2 AAAATGGAAACGGGGTGACTT 
 
GGCTGCATACATTGGGTTTTCA 
 
18S GAGCGGTCGGCGTCCCCCAACTT
C 
 
GCGCGTGCAGCCCCGGACATCTA
A 
 
hIL6 ACTCACCTCTTCAGAACGAATTG 
 
CCATCTTTGGAAGGTTCAGGTTG 
 
mIL6 TAGTCCTTCCTACCCCAATTTCC 
 
TTGGTCCTTAGCCACTCCTTC 
 
hMCP1 GAGGAACCGAGAGGCTGAGACTA
A  
 
GGGGAATGAAGGTGGCTGCTAT 
 
mMCP1 TTAAAAACCTGGATCGGAACCAA 
 
GCATTAGCTTCAGATTTACGGGT 
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hIL8 CTAGGACAAGAGCCAGGAAGAA 
 
GGGTGGAAAGGTTTGGAGTATG 
 
hIL1B ATGATGGCTTATTACAGTGGCAA 
 
GTCGGAGATTCGTAGCTGGA 
 
mIL1B GCAACTGTTCCTGAACTCAACT 
 
ATCTTTTGGGGTCCGTCAACT 
  
hMMP1 GGCCCACAAACCCCAAAAG 
 
ATCTCTGTCGGCAAATTCGTAAGC 
 
hMMP3 GACCCAAATGCAAAGAAAGTGACA 
 
AAAAATGACCGGCAAGATACAGAT 
 
hMMP9 TGTACCGCTATGGTTACACTCG 
 
GGCAGGGACAGTTGCTTCT 
 
mMMP9 GCAGAGGCATACTTGTACCG 
 
TGATGTTATGATGGTCCCACTTG 
 
ha-SMA TTCAATGTCCCAGCCATGTA GGAAACGTTCATTTCCGATG 
hC5 ACAGTCATAGAGTCTACAGGTGG 
 
CCAACTGGTCAAGCGAATCTT 
 
hFTH1 TCCTACGTTTACCTGTCCATGT 
 
GTTTGTGCAGTTCCAGTAGTGA 
 
mFTH1 CAAGTGCGCCAGAACTACCA 
 
GCCACATCATCTCGGTCAAAA 
 
hTFR1 GTGTGCAGTGTCGGAGCAT 
 
CATCGGATGGAATGACGCTTT 
 
mTFR1 ATGCCGACAATAACATGAAGGC 
 
ACACGCTTACAATAGCCCAGG 
 
hFerroportin TGGATGGGTTCTCACTTCCTG 
 
GTCAATCCTTCGTATTGTGGCAT 
 
 
Table 2: List of human (h) and mouse (m) primer sequences used in study 
Immunoblotting 
        Lysates from cultured cells and mouse pancreatic tissue were prepared using 
RIPA buffer (50 mM Tris-HCl [pH 7.4], 150mM NaCl, 1% Triton X-100, 1mM EDTA, 
0.5% deoxycholate), 1mM sodium orthovanadate, 1mM sodium fluoride, 1 mM 
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phenylmethylsulfonyl fluoride and a cocktail of protease inhibitors ( Roche, 
Indianapolis, IN). Protein concentrations were determined using the Protein Assay 
Dye Reagent (Bio-Rad, Hercules, CA). Conditioned media was prepared by 
collecting media from treated or untreated cells in 10mm plates and concentrating 
the media ten-fold by using Ultra-15 centrifugal filter units (EMD Millipore, Billerica, 
MA). Samples were prepared to have equal amounts of protein per volume and 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were transferred to a nitrocellulose membrane, blocked with 5% 
milk in PBST for one hour and incubated with primary antibodies (Table 3) overnight 
at 4 °C. Membranes were then incubated with corresponding secondary antibodies 
labeled with IRDye® near-infrared fluorescent dyes for one hour. Protein signal was 
detected by visualizing near-infrared fluorescent signals with the Odyssey® imaging 
system (Li-Cor, Lincoln, NE).  
Primary antibody Source Dilution Secondary antibody, 
source 
Monoclonal Rat 
anti LCN2 
R&D Systems 
(Minneapolis, MN) 
1:1000 IRDye® 800CW Goat anti-
Rat, 1:10,000, (Li-Cor, 
Lincoln, NE) 
Rabbit polyclonal 
anti-SLC22A17  
Thermo Scientific  1:1000 IRDye® 650 Goat anti-
Rabbit, 1:10,000, (Li-Cor, 
Lincoln, NE) 
Rabbit polyclonal 
anti-C5  
Abcam (Cambridge, 
MA) 
1:1000 IRDye® 650 Goat anti-
Rabbit, 1:10,000, (Li-Cor, 
Lincoln, NE) 
 
Table 3: List of primary used in immunoblotting  
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Lentivirus-mediated SLC22A17 knockdown 
        Mission shRNA bacterial glycerol stock plasmids for SLC22A17 were obtained 
from Sigma Aldrich (St. Louis, MO) with the following sequence: 
CCGGGCGATTCCTACAGCGAATGATCTCGAGATCATTCGCTGTAGGAATCGCT
TTTTG. Non-targeting controls were used along with both shRNA plasmids. 2.3 µg 
of the each respective plasmid was con-transfected with the envelope PMD2.G (2 
µg) and packaging PsPAX2 (4.7 µg) plasmids into 293FT cells using Lipofectamine 
2000 (Life Technologies). After an overnight incubation, fresh media containing 10% 
FBS was added to the cells. 24 and 48 hours later, virus-containing media was 
collected and filtered through 0.45 µm filters. HPSCs were cultured in 6-well plates 
and incubated with 500 µL of virus supernatant along with 4 µg of polybrene for 24 
hours. Stable knockdown cells were selected using 1 µg/mL puromycin. SLC22A17 
was also transiently knockdown using plasmids and siRNAs. siRNA transfection was 
performed using 12 µL of HiPerfect transfection reagent (QIAGEN, Valencia, CA) 
and 50nM of the respective siRNA for 24 hours.   
Recombinant human LCN2 and Deferoxamine treatments  
        HPSCs with endogenous or knockdown of SLC22A17 were plated at 2 x 105 
cells per well in 6-well plates or at 1 x 106 in 10mm dishes. The next day, cells were 
washed twice with PBS and serum-starved overnight. Before treatment, cells were 
again washed twice with PBS. Recombinant human LCN2 (rhLCN2) (R&D Systems, 
Minneapolis, MN) was resuspended in 25mM MES and 150mM NaCl at pH 6.5. 
Cells were treated with different concentrations of rhLCN2 at different time points in 
order to determine the optimal concentration and treatment time. Most experiments 
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were conducted using 100 or 500 ng/mL rhLCN2 for 24 to 48 hours. Deferoxamine 
(DFO) (Sigma Aldrich, St. Louis, MO) was diluted in water and was added to cells at 
a concentration of 20µM for 24 to 48 hours. 
Iron colorimetric assay 
        The BioVision colorimetric iron assay kit ( BioVision, Milpitas, CA) was used to 
measure ferrous iron (Fe2+). Briefly, cells were lysed in Iron Assay Buffer and 
centrifuged at 12,000 g for ten minutes. 30µg of cell lysate with a total volume of 
50µL was added to a 96-well plate along with 55µL of Iron Assay Buffer. A standard 
curve of 0, 2, 4, 6, 8, and 10 nMol was generated using the Iron Standard provided. 
Samples and iron standards were incubated at room temperature for thirty minutes. 
100µL of Iron Probe was then added to each well and incubated at room 
temperature protected from light for one hour. Absorbance was measure at 593nm 
in a microplate reader.   
Cytokine protein array  
        Concentrated conditioned media (200 uL) was used to detect the expression of 
cytokines using the Proteome Profiler human cytokine array panel A (R&D Systems, 
Minneapolis, MN). Conditioned media was diluted in array buffers 4 and 5 and then 
incubated with 15uL of the biotinylated cytokine antibody cocktail for one hour. Each 
sample was added to a nitrocellulose membrane spotted in duplicate with selected 
capture antibodies and incubated overnight at 4 °C. The following day, each 
membrane was washed and incubated with Streptavidin-HRP for thirty minutes at 
room temperature. After a second round of washing, membranes were incubated 
with chemiluminescent reagents and exposed to X-ray film for ten minutes. Positive 
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signals were analyzed with the ImageJ software protein array analyzer plug-in 
(created by Gilles Carpentier, Faculté des Sciences et Technologies, Université 
Paris) to obtain the pixel density for each spot on the array.  
LCN2 ELISA  
        Human and mouse LCN2 Quantikine ELISA kits (R&D Systems, Minneapolis, 
MN) were used to measure LCN2 levels in human and mouse serum samples. 
Briefly, 50µL of serum diluted in Assay Diluent RD1-34, as well as LCN2 standards, 
were added to a 96-well microplate pre-coated with LCN2 monoclonal antibody and 
incubated for two hours at room temperature. After a series of four washes, an 
enzyme-linked monoclonal antibody against LCN2 was added to each well and 
incubated for two hours at room temperature. After washing, 100µL of substrate 
solution was added to each well and incubated for thirty minutes while protected 
from light. 100µL of Stop solution was then added and the optical density was 
determined using a microplate reader se to 450nm. 
Statistics  
        Statistical analysis was performed using the Prism 5 software program 
(GraphPad Software San Diego, CA). Results are expressed as the mean ± 
standard error of the mean. A t-test or one-way analysis of variance was performed 
on sex-matched littermates. The percentage of survival was analyzed using the 
Mantel-Cox method. The median survival in days was presented. P levels less the 
0.05 were considered significant.  
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Chapter 3: 
Lipocalin 2 depletion attenuates ECM 
remodeling, immune cell infiltration 
and delays pancreas cancer growth 
with increased survival 
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        Within the last two decades, many animal experimental models have been 
developed to reproduce and understand pancreatic cancer (Guerra and Barbacid, 
2013; Herreros-Villanueva et al., 2012). Many of these models have focused on the 
genetic activation of mutant KRas oncogenes. In addition to knocked-in mutant kras, 
additional mutations and deletions of genes known to be altered in PDAC 
development such as trp53, ink4a and smad4 have been explored. In particular, the 
PDX-1-Cre; LSL-KrasG12D; LSL-Trp53R172H/- (KPC) model of pancreas cancer has 
been well studied and shown to be clinically representative of human disease. These 
animals express both mutant KRas and Trp53 genes in tissue progenitor cells of the 
developing mouse pancreas which is driven by the pancreatic-specific promoter 
PDX-1. The pancreas of such animals are then able to develop the full range of 
pancreatic intraepithelial neoplasia observed in humans (Hingorani et al., 2005). 
Specifically, PanIN-1 lesions have been observed early in four week old mice. With 
increasing age, these animals develop higher-grade PanINs, PDAC within two to 
three months and display a mean survival of five months. Similarly, animals with 
complete deletion of Trp53 generate the same lesions with a shortened median 
survival of three months (Guerra and Barbacid, 2013).  
        In addition to genetically engineered mouse models, tumor xenograft mouse 
models of PDAC have been commonly used in the last decade (Herreros-Villanueva 
et al., 2012). Some of these models rely on the injection of culture-grown human 
PDAC cells into mice or even the transplantation of a human tumor mass (Herreros-
Villanueva et al., 2012). Appropriately, severely compromised immunodeficient mice 
(SCID) (with affected B and T lymphocytes) or athymic nude animals (unable to 
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generate mature T lymphocytes) are used in such studies. In addition to having the 
option to use variable human tumor sources and animals, the location of the implant 
is also variable. The subcutaneous xenograft model allows for the implantation of 
tumor cells or mass in between the dermis and the underlying muscle of a flank, the 
back or footpad of an animal. An advantage of this model is the ability to visually 
assess tumor growth or response to therapy over time (Herreros-Villanueva et al., 
2012). This model is widely used as a preclinical model to test response to certain 
therapies which can indicate new potential therapeutic options. However, one of the 
biggest disadvantage to using this model is the irrelevant subcutaneous tumor 
microenvironment. This has been suggested as a reason for which drug treatments 
that have been shown to be successful in this model are not effective for treating 
human disease.  
        Orthotopic xenograft models on the other hand, allow for the study of 
appropriate organ specific biology. In this model, tumor cells are directly injected into 
the pancreas of a mouse and therefore allows for gene expression studies in the 
presence of relevant tumor-host interactions. Disadvantages in using this model 
includes a technically challenging procedure, longer recovery times and lower 
throughput imaging methods. Despite these challenges, the orthotopic model is 
preferred due to its clinical relevance.  
        Although many prefer the use of GEMMs, the use of syngeneic (allograft) 
orthotopic models is becoming widespread. The syngeneic model consists of tumor 
tissue derived from and implanted into animals with the same strain background. 
The most significant advantage to using this model is that the host immune system 
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is normal and it may much closely represent relevant tumor-host interactions 
compared to any other xenograft models. Further, because of their intact immune 
system, syngeneic models are becoming the “go to” reliable model for 
immunotherapy studies.  
        Previous in vivo studies have reported contradicting roles of LCN2 in PDAC. 
The first study made use of an orthotopic xenograft model in nude mice in which 
PDAC cells modified to overexpress LCN2 were injected directly into the mouse 
pancreas (Tong et al., 2008). Tumors obtained from LCN2 overexpressing cells 
were found to be significantly smaller than in the control animals. In the most recent 
study, PDAC cells overexpressing LCN2 or with LCN2 knockdown were injected 
subcutaneously into SCID mice. In this model, tumors from LCN2 overexpressing 
cells were markedly larger than tumors developed from cells with silenced LCN2 
expression. These contradicting findings highlight the need of further studies in order 
to understand the role of LCN2 in PDAC.   
LCN2 depletion delays tumor growth in a syngeneic orthotopic PDAC model 
        Given the important crosstalk between tumor cells and the tumor 
microenvironment in PDAC, in vivo studies were performed in a syngeneic 
orthotopic model. LCN2 has been previously shown to be present in significant 
higher levels in both the serum and the pancreas of KPC mice with high-grade 
neoplastic lesions and cancer compared to normal mice (Slater et al., 2013).  Tumor 
cells derived from a PDX-1-Cre; LSL-KrasG12D; LSL-Trp53-/- (KPC) mouse with 
PDAC were first analyzed for LCN2 expression. KPC cells derived from tumor 
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demonstrated significantly higher mRNA levels of LCN2 compared to normal 
pancreas. (Figure 3) 
 
Figure 3. mLCN2 expression is higher in tumor-derived KPC-Luc cells 
compared to normal pancreas. The mRNA levels of mLCN2 were examined in 
KPC-LUC cells and from the histological normal pancreas of mice. ****P<0.0001 
(Student t-test) 
        Half a million KPC-LUC cells were directly injected into the pancreas of 
C57BL/6 mice with either wild type LCN2 (LCN2+/+) or whole-body LCN2 silenced 
(LCN2-/-) expression. Tumor growth was visualized by injecting mice with D-Luciferin 
(150 µg/mouse; Caliper Life Sciences) and measuring bioluminescence using the 
IVIS imaging system (Caliper Life Sciences) (Ma et al., 2013). All animals (LCN2+/+ 
n=20 and LCN2-/- n=17) were imaged on a weekly basis until sacrifice was required. 
We first assessed the presence of KPC-LUC cells by imaging all animals the day 
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after tumor cell implantation. The pancreas of each mice revealed a bioluminescent 
signal indicative of the presence of KPC-LUC cells (Figure 4) . In fact, there seemed 
to be no difference in the bioluminescent signal given off by LCN2+/+ mice compared 
to LCN2-/- animals at one week. This indicated that similar amounts of KPC-LUC 
cells were injected and present in both groups of animals. 
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Figure 4. KPC-Luc cells are present in mouse pancreas after injection. The 
bioluminescent signal detected via the IVIS imaging system indicates the presence 
of tumor cells in the pancreas of mice after surgery.  
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        By week three after surgery, most LCN2+/+ animals had developed large 
tumors. The size of the tumors was visualized by a strong bioluminescent signal as 
seen in Figure 5a. At this time point, it was quite obvious that LCN2 depletion 
delayed tumor growth as observed by the small amount of signal detected in the 
LCN2-/- mice. Of note, the signal previously seen in week one appears to be almost 
absent due to the normalization of all images at the same scale. Further, the 
radiance given off by each signal was measured using the Living Image® software. 
Quantification of the bioluminescent signal indicated that LCN2+/+ animals developed 
a significantly higher fold change in average radiance compared to LCN2-/- mice 
starting at three weeks post-surgery as seen in Figure 5b.  
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Figure 5. LCN2 depleted animals display delayed tumor growth. After injecting 
KPC-LUC cells to either LCN2+/+   or LCN2-/- animals, luciferase signal representing 
tumor growth was measured every week. (A) By the third week, LCN2+/+ animals 
demonstrated very high signal while LCN2-/- animals presented significantly lower 
signal. (B) Living Image® software was used to quantify the average radiance given 
off by each animal. The graph demonstrates that significance in signal was achieved 
at week 3. ***P<0.001 (student t test) 
LCN2 depletion increases survival 
        Continued monitoring of these animals allowed us to notice that LCN2+/+ mice 
developed bigger tumors at a faster rate than the LCN2-/- animals. In fact, the 
survival analysis of these experiments revealed that the median survival of LCN2-/- 
animals was over three-fold higher than LCN2+/+ mice, 105 days versus 33 days 
respectively (Figure 6). Further, all of the LCN2+/+ mice had to be sacrificed due to 
morbidity by 104 days after KPC-LUC cell implantation while about fifty percent of 
LCN2-/-  animals were still alive at that time. In fact, several of the LCN2-/-  animals 
were sacrificed without signs of morbidity at 282 days after KPC-LUC cell 
implantation in order to analyze the pancreas of this group of animals. The pancreas 
of these animals showed no sign of bioluminescence (Figure 7c) revealing that 
KPC-LUC cells were not present in the pancreas after 282 days. In contrast, the 
small number of LCN2-/-  mice that did develop tumor showed signs of KPC-LUC cell 
presence in some areas of their pancreas. (Figure 7b).  Moreover, the pancreas 
from most LCN2+/+ animals showed very high amounts of bioluminescence in the 
whole pancreas tumor (Figure 7a). 
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Figure 6. LCN2 depleted animals display prolonged survival. LCN2+/+ animals 
exhibited a decreased mean survival of 33 days while LCN2-/- animals presented a 
three-fold higher mean survival of 105 days. ****P<0.0001 (Mantel-Cox test)  
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Figure 7. KPC-LUC cells do not survive in all LCN2-/-  mice. (A) Pancreas 
resected from a LCN2+/+ animal 37 days after tumor cell implantation. (B) Pancreas 
from a LCN2-/-  animal showing some tumor growth 86 days after tumor cell 
implantation. (C) The pancreas from a LCN2-/-  animal showing no sign of KPC-LUC 
cell presence 282 days after implantation.   
  
A 
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         As LCN2 is a secreted molecule and is detected in serum, we examined if 
serum LCN2 levels changed in mice after tumor cell implantation. We observed that 
serum LCN2 levels significantly increased in LCN2+/+ mice after KPC tumor cell 
injection compared to control animals without any tumor cells. On the other hand, 
LCN2 serum level changes were undetectable in LCN2-/-  animals (Figure 8). The 
fact that LCN2 serum levels did not significantly increase in LCN2-/-  mice also point 
out the lack of KPC-LUC cell presence in most of these animals at three weeks after 
implantation. 
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Figure 8. LCN2+/+ mice secrete higher levels of LCN2 after tumor cell 
implantation. LCN2 ng/ml in serum from mice +/- LCN2 expression and +/- tumor 
cells in the pancreas after 3 weeks. **p<0.01 (student t test) 
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  LCN2 depletion attenuates ECM remodeling 
    Upon closer examination of the pancreas of all animals, we observed that most 
LCN2-/- mice had little to no ECM remodeling compared to LCN2+/+animals. (Figure 
9) The Hematoxylin and eosin (H&E) stain of the LCN2+/+animals, shown in the first 
panel in Figure 9a, showed the extensive presence of tumor with just a small 
amount of adjacent seemingly normal pancreas. In contrast, we observed a mostly 
normal pancreas with unperturbed pancreatic acinar cells in LCN2-/- mice as shown 
in the first panel in Figure 9b. Picrosirius red staining of the pancreas of these 
animals (second panel in Figure 9) revealed an extensive remodeling of the ECM in 
LCN2+/+mice demonstrated by an increase in the presence of collagen networks. 
Specifically, this staining showed expression of Collagens I and III which was not 
visible in the pancreas of LCN2-/- animals. Additionally, staining for α-SMA was 
positive for LCN2+/+animals compared to LCN2-/-mice (third panel in Figure 10). This 
observation indicated the presence and activation of mouse pancreatic stellate cells 
which are key regulators of the pancreas stroma.   
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 Figure 9. LCN2 depletion attenuates ECM remodeling. H&E staining, Picrosirius 
red staining (indicating presence of Collagens I and III) and staining for α-SMA 
(indicating presence of mouse pancreatic stellate cells) for (A) LCN2 wild type and 
(B) LCN2 null animals injected with KPC-LUC cells. 
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LCN2 depletion attenuates the inflammatory response in mouse pancreas 
        LCN2 has been previously shown to play a role in innate immunity due to its 
upregulation after bacterial infection and secretion by neutrophils and macrophages 
(Meheus et al., 1993; Nielsen et al., 1996). In addition, inflammation is also 
responsible for driving the expression of LCN2 (Rodvold et al., 2012). Pro-
inflammatory cytokines such as IL-1B, TNF-a and IL-17 are capable of inducing 
LCN2 expression (Li and Chan, 2011). A study examining the effect of LCN2 
depletion in an obesity mouse model revealed that LCN2 deficiency attenuated 
inflammation in adipose tissue (Law et al., 2010). Given the amounting evidence 
linking LCN2 to inflammation, we decided to assess the effect of LCN2 depletion in 
our syngeneic orthotopic PDAC model. We performed IHC staining for the leukocyte 
marker CD45 and the macrophage maker F4/80 (Figure 10a). Results from the 
staining demonstrated a significant infiltration of inflammatory cells in the pancreas 
of LCN2+/+animals. However, in LCN2-/-mice, we observed little to no presence of 
these inflammatory cells. Further, LCN2+/+animals were found to secrete significantly 
higher levels of the macrophage-colony stimulating factor (M-CSF) (Figure 10b). M-
CSF is a cytokine that influences the differentiation of hematopoietic cells into 
macrophages. In addition to secreting M-CSF, analysis of bulk pancreas tissue 
revealed that LCN2+/+animals synthesized significantly higher levels of the pro-
inflammatory cytokines IL-6, IL-1B and MCP1 Figure 11. Thus, these results 
suggest a role for LCN2 in promoting an inflammatory response in the tumor 
microenvironment.  
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 Figure 10. LCN2 depletion attenuates immune cell infiltration. (A) IHC staining 
for the leukocyte marker CD45 and the macrophage maker F4/80 revealed an 
immune cell infiltration in LCN2+/+mice. (B) The cytokine M-CSF responsible for 
hematopoietic cell differentiation to macrophages is significantly upregulated in 
LCN2+/+mice. **p=<0.01 (student t-test) 
Figure 11. LCN2+/+ mice synthesize high amounts of pro-inflammatory 
cytokines. IL-6, MCP-1 and IL-1B mRNA levels were highly upregulated in LCN2+/+ 
animals compared to in LCN2-/-mice. *p=<0.05, **p=<0.01 (student t-test) 
 
 
 
48 
 
        Ki-67 is an important biological marker indicative of cellular proliferation 
(Schluter et al., 1993). This molecular marker is commonly used in cancer studies as 
an index to characterize proliferating tumor cells (Ammendola et al., 2015; 
Kalogeraki et al., 1997). In fact, Ki-67 has been previously used as an index of 
PDAC growth in both human and mouse tissue samples (Ammendola et al., 2015; 
Gardovskis et al., 2012; Yamamoto et al., 2004). We examined cellular proliferation 
by staining LCN2+/+ and LCN2-/- mouse tissue for Ki-67 (Figure 12a). The resulting 
staining patterns clearly indicated a vast amount of proliferating cells in LCN2+/+ 
animals. In contrast, little to no actively growing cells were visible in LCN2-/- mice. 
        In addition to examining Ki-67 as an index of tumor growth, we further analyzed 
the serum of these animals for other putative PDAC biomarkers including sICAM-1, 
IGFBP-1 and TIMP-1 (Brand et al., 2011; Slater et al., 2013; Wolpin et al., 2007). 
(Figure 12b) shows that LCN2+/+ animals secreted significantly higher quantities of 
all three molecules compared to LCN2-/- mice. These data suggest the potential of 
LCN2 to be used as a putative prognostic marker for PDAC in conjunction with these 
other molecules. 
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Figure 12. LCN2 depletion decreases the expression of PDAC tumor markers. 
(A) Ki-67, a commonly used marker for tumor cell proliferation, is highly expressed in 
the pancreas of LCN2+/+ mice. (B) The putative PDAC biomarkers sICAM-1, IGFBP-
1 and TIMP-1 are secreted in significant higher levels in LCN2+/+ mice. ***p=<0.001, 
****p=<0.0001 (student t-test) 
Tumors from LCN2 depleted animals demonstrate attenuated stromal 
remodeling 
        While 7 out of 17 LCN2 null animals did not develop any tumors, the remaining 
10 animals did develop tumors. When compared to LCN2(+/+) animals, the LCN2 null 
tumors exhibited attenuated collagen, α-SMA, CD45, F4/80 and Ki67 staining 
(Figure 13). This again demonstrated that even though tumors grew, the presence 
of proliferative cells was diminished in animals lacking LCN2. Thus, these results 
suggest a role for LCN2 in delaying tumor growth and stromal remodeling in a 
mouse model of PDAC.  
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Figure 13. LCN2 depletion attenuates ECM remodeling, immune infiltration and 
tumor cell proliferation in LCN2 null mice with tumors. H&E staining, IHC for 
collagen, α-SMA, F4/80, CD45 and Ki67.LCN2 null animals injected with KPC-LUC 
cells that did develop tumors still maintained lower collagen, a-SMA expression, 
inflammatory cell infiltration and tumor cell growth compared to tumors from 
LCN2(+/+) animals. 
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LCN2 null animals express lower levels of the LCN2-specific receptor 
SLC22A17 and iron responsive genes 
        SLC22A17 and LRP2 are the two known receptors that are able to bind and 
endocytose LCN2 (Chakraborty et al., 2012). While LRP2 is also able to bind a 
series of other ligands including the iron binding molecules transferrin and 
lactoferrin, SLC22A17 is LCN2 specific (Chakraborty et al., 2012). In our syngeneic 
study, LCN2-/- animals showed a significant reduction in SLC22A17 mRNA 
expression in the pancreas (Figure 14 A). These results seem to suggest a 
previously unidentified role for SLC22A17 in PDAC malignancy. Moreover, this 
suggestion is further aided by the fact that high LCN2 and SLC22A17 expression 
has been correlated with malignancy in hepatocellular and endometrial cancer. 
        In addition, the pancreas of LCN2 depleted animals expressed lower levels of 
the iron responsive molecules ferritin (FTH1) and the transferrin receptor (TFR1) 
(Figure 14 B). Because FTH1 mRNA levels increase in response to higher iron 
levels, these results suggest a higher iron content in pancreas tissue after tumor cell 
implantation in animals with endogenous LCN2 expression. While TFR1 expression 
typically increases when iron levels decrease, in our study, TFR1 levels were 
significantly higher in animals with wild type LCN2 expression. TFR1 expression has 
been linked to a malignant cell presence in pancreas cancer (Ryschich et al., 2004). 
Thus, it is possible that the higher levels of TFR1 in LCN2+/+ mice is due to increased 
presence of malignant cells after tumor cell implantation.  
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Figure 14. LCN2 depleted animals express lower levels of the LCN2 receptor 
SLC22A17 and iron responsive molecules.  (A) mSLC22A17 mRNA levels are 
significantly higher in the bulk pancreas of LCN2+/+ mice. (B) A decrease in FTH1 
A 
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54 
 
expression indicates reduced amounts of iron levels. (C) Decreased TFR1 would 
usually indicate higher iron levels however, TFR1 has been shown to be a marker of 
malignancy in PDA. This data suggests increased malignancy in LCN2(+/+) animals. 
**p<0.01, ***p<0.001 (student t-test) 
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Chapter 4: 
Lipocalin 2 Stimulates a Receptor and 
Iron-Mediated Pro-Inflammatory 
Response in Human Pancreatic 
Stellate Cells 
  
56 
 
        LCN2 was first isolated over two decades ago as a complex with MMP9 
(Hraba-Renevey et al., 1989). Six years later, LCN2 was first detected in the plasma 
of healthy individuals (Axelsson et al., 1995). In the following years, it was found that 
LCN2 was synthesized and secreted by adult neutrophils, macrophages, adipocytes, 
breast, lung and liver among other normal adult tissue (Chakraborty et al., 2012; 
Cowland and Borregaard, 1997; Kjeldsen et al., 2000; Wang et al., 2007). The fact 
that LCN2 was expressed by immune cells and in tissues that are often exposed to 
microorganisms suggested a role for LCN2 in regulating the inflammatory response. 
This was confirmed as LCN2 was found to be able to combat bacterial infections by 
binding bacterial siderophores that have a high affinity to iron (Clifton et al., 2009; 
Yang et al., 2002). LCN2 thus deprived bacteria from essential iron sources leading 
to diminished bacterial growth and survival (Chakraborty et al., 2012). Moreover, it 
was revealed that LCN2 altered iron stores in mammalian cells by transporting iron 
through its receptors SLC22A17 and LRP2 (Devireddy et al., 2005). Given that iron 
has important roles in both immunity and cancer, these studies suggest potential 
mechanisms as to how LCN2 may modulate the inflammatory response in benign 
and malignant diseases.    
        Aberrant LCN2 expression has been reported in thyroid, ovarian, breast, 
endometrial, colorectal, gastric, hepatocellular, oesophageal, lung and pancreatic 
cancers (Bauer et al., 2008; Candido et al., 2014; Li and Chan, 2011; Lippi et al., 
2014; Moniaux et al., 2008; Nielsen et al., 1996). Many studies have shown that 
LCN2 overexpression correlates with tumor size, aggressiveness and invasiveness 
implicating LCN2 as a marker of malignancy (Chakraborty et al., 2012; Lippi et al., 
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2014). In pancreatic cancer, LCN2 was first found as a secreted molecule in eight 
human pancreatic cancer cell lines with weak expression in normal pancreatic tissue 
(Furutani et al., 1998). This was later confirmed in additional PDAC cell lines with 
varied levels of expression ranging from very weak to up to a thirty-fold increase 
compared to normal pancreatic tissue (Han et al., 2002). An immunohistochemical 
assessment revealed that all human PDAC tissue samples were positive for LCN2 
expression while normal tissue stained very weakly for LCN2 (Moniaux et al., 2008). 
More importantly, this study demonstrated that LCN2 expression was detectable in 
pre-neoplastic lesions as early as PanIN-1. The majority of the staining patterns 
were localized to pancreatic duct or cancer cells with a small amount of staining in 
the tumor stroma. When we examined LCN2 expression using a microarray to 
measure RNA levels in 15 PDAC, 16 pancreatitis and 10 normal tissue samples, we 
found that LCN2 is significantly overexpressed in PDAC samples compared to both 
normal and pancreatitis samples (Figure 15a). Moreover, LCN2 was differentially 
regulated in PDAC compared to other lipocalin family members (Figure 15b). These 
results suggest the potential use of LCN2 as a potential PDAC biomarker. Others 
have continued to investigate LCN2 in PDAC with the main focus placed on the 
effect of overexpressing or silencing LCN2 expression in PDAC cell lines. While it is 
well known now that LCN2 expression in PDAC cell lines is variable, there have 
been no studies that indicate whether LCN2 is expressed in human pancreatic 
stellate cells (hPSCs).  
        hPSCs are active members of the pancreatic tumor stroma. Extensive studies 
have shown that hPSCs have roles in pancreatic inflammation, modulation of the 
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Figure 15. LCN2 is differentially upregulated in PDAC. PDAC (n=15), pancreatitis 
(n=16) and normal (n=10) tissue samples were analyzed using an Illumina 
microarray for LCN2 expression. (A-B) LCN2 is significantly and differentially 
upregulated in PDAC compared to other lipocalin members in pancreatitis and 
normal samples. ***p<0.001 (student t-test) 
A 
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ECM and in PDAC (Duner et al., 2010; Liu and Du, 2015; Omary et al., 2007; Pandol 
and Edderkaoui, 2015). Specifically, hPSCs have the ability to synthesize and 
secrete cytokines, growth factors and ECM molecules that allow for the 
establishment of the tumor microenvironment. Examples of the molecules secreted 
by hPSCs include Collagen I, Laminin, Fibronectin, Matrix Metalloproteinases 
(MMPs), tissue inhibitors of metalloproteinases (TIMPs), stromal-derived factor 1 
(SDF-1), FGF, IGF-1, PDGF, Interleukins 1, 6, 8 and M-CP1 in addition to other 
molecules (Andoh et al., 2000b; Duner et al., 2010; Fokas et al., 2015; Omary et al., 
2007). These factors are then able to exert a paracrine effect on neighboring cells 
which can alter the proliferation, migration and invasion potential of tumor cells. 
Additionally, cytokines and growth factors can also have an autocrine effect on 
hPSCs resulting in the chronic activation and secretion of these factors.  Moreover, 
hPSCs have been shown to have the potential to regulate macrophages and 
Myeloid-derived suppressor cells (MDSCs) via secretion of IL-6 (Mace et al., 2013; 
Shi et al., 2014). Given the important role of hPSCs in the host-tumor crosstalk as 
well as its important role in balancing the pancreatic stromal architecture, we 
investigated the role of LCN2 in these cells and whether any resulting effects were 
mediated by the LCN2 receptors and iron.  
Human Pancreatic Stellate Cells express LCN2 receptors but lack LCN2 
        In order to determine how LCN2 expression could impact hPSCs, we first 
assessed if LCN2 was synthesized and secreted by hPSCs. We isolated RNA and 
cDNA from a series of two immortalized “normal” pancreatic epithelial cells, six 
PDAC cells and two different immortalized hPSCs according to the methods 
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indicated in chapter two. Human pancreatic ductal epithelial cells (HPDEs) and 
human pancreatic nestin-expressing cells (HPNEs) were included in this analysis as 
a negative control for LCN2 expression as many groups have reported weak to no 
LCN2 presence in the normal pancreas. The six different PDAC cells included 
BXPC3, HPAC, CAPAN1, CAPAN2, MIAPACA2 and MPANC96 cells which have 
been previously examined for LCN2 expression (Leung et al., 2012; Tong et al., 
2008). Similar to these previous studies, we confirmed that out of our group of cells, 
CAPAN1 and CAPAN2 had the highest levels of LCN2 expression followed by 
BXPC3, HPAC and MPANC96 and that Miapaca2 cells did not express LCN2 
(Figure 16a). The corresponding levels of LCN2 secretion or lack thereof have been 
previously shown (Leung et al., 2012; Tong et al., 2008). More importantly, we 
reported for the first time that neither hPSC line expressed any LCN2 mRNA levels. 
Moreover, upon examining cell supernatants and using recombinant human LCN2 
(rhLCN2) as a positive control, we further confirmed that hPSCs do not secrete 
LCN2 (Figure 16b). 
        SLC22A17 was first identified as an LCN2 receptor after being isolated from a 
murine cell derived cDNA library (Devireddy et al., 2005). The clone identified 
actually matched a protein called brain type organic cation transporter (BOCT) 
suggesting a physiological role in the brain. Although the OCT/SLC22 family 
members have been shown to be able to transport various organic cations, anions 
and zwitterions, a rat BOCT/SLC22A17 was unable to transport any of the typical 
SLC22 substrates (Bennett et al., 2011). Nevertheless, SLC22A17 has been 
reported to bind and mediate the cellular uptake of LCN2 (Cabedo Martinez et al., 
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2016; Devireddy et al., 2005; Fang et al., 2007). Megalin, LRP2, has also been 
shown to be a receptor for LCN2 although it also binds numerous structurally 
unrelated molecules including aprotinin, vitamin D3 and lactoferrine (Hvidberg et al., 
2005; Miyamoto et al., 2011a). Upon examining the expression of these two LCN2 
receptors, we observed that both hPSC lines expressed both SLC22A17 and LRP2 
(Figure 15c-d). Moreover, both of these cell lines expressed significantly higher 
levels of both receptors compared to PDAC cells and normal epithelial pancreatic 
cells. To the best of our knowledge, we are the first group to investigate and report 
the presence of these cell membrane receptors on hPSCs and on pancreatic normal 
and cancer cells. 
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 Figure 16. Human Pancreatic Stellate Cells (HPSCs) express LCN2 receptors 
SLC22A17 while lacking LCN2 expression. (A) LCN2 mRNA levels were 
examined for human pancreatic immortalized normal epithelial cells (HPDE, HPNE), 
PDAC cell lines (BXPC3, HPAC, CAPAN 1&2, MIAPCA2, MPANC69) and two 
immortalized human pancreatic stellate cells (HPSC1 &2) (B) Western blot of cell 
supernatants from BXPC3 confirm LCN2 secretion while HPSC do not secrete LCN2 
(C) HPSCs express the LCN2-specific receptor SLC22A17 (D) HPSCs express the 
A 
Cell Supernatant 
BxPC3 HPSC rhLCN2 
+ Control 
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second known LCN2 receptor LRP2. *p<0.05,***p<0.001, ****p<0.0001 (student t-
test) 
Ectopic rhLCN2 induces the expression of a pro-inflammatory cytokine and an 
iron responsive molecules  
        The fact that PDAC cells and inflammatory cells secrete LCN2 and hPSCs 
express LCN2 receptors led us to ask whether LCN2 had any effect on the 
expression of pro-inflammatory molecules. Interleukin-6 (IL-6) is a well-studied pro-
inflammatory cytokine that has been reported to be upregulated during pancreatitis 
in humans and in mice (Talar-Wojnarowska et al., 2009).Many groups have 
identified IL-6 as one of the cytokines secreted by activated hPSCs (Fokas et al., 
2015; Omary et al., 2007). Consequently, IL-6 can act in both a paracrine and 
autocrine manner to stimulate neighboring tumor cells and further activate hPSCs 
(Lunardi et al., 2014). Moreover, IL-6 has been shown to mediate PanIN formation 
and PDAC development via downstream signaling involving STAT3 (Lesina et al., 
2011). A more recent study indicated that while IL-6 expression was not necessary 
for PanIN formation, it was a key player in the maintenance and progression of 
PanIN lesions in a Kras driven model (Zhang et al., 2013). 
      As IL-6 is implicated in both inflammation and in PDAC, we examined if LCN2 
could induce IL-6 expression in hPSCs. 2.0 x 105 cells were plated in six-well plates, 
they were serum-starved overnight and then treated with either 50, 100 or 500 
ng/mL of recombinant human LCN2 (rhLCN2) for either 15, 30 or 60 minutes. RNA 
and cDNA were isolated after this treatment and RT-qPCR was performed to assess 
IL-6 mRNA levels. We observed that while all doses resulted in higher IL-6 levels 
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compared to untreated cells, the 50 ng/mL dose had minimal effects at all three time 
points that did not reach significance (Figure 17a). The 100 ng/mL dose however, 
allowed for the significant upregulation of IL-6 expression at all time points with the 
highest effect occurring at 60 minutes of treatment. Similarly, the 500 ng/mL dose 
induced significant IL-6 expression at comparable levels to that of the 100 ng/mL 
dose. Because the serum LCN2 levels in pancreatic patients have been found to be 
around 111 ng/mL, we decided to continue further experiments using either 100 or 
500 ng/mL rhLCN2. This experiment served as the first evidence that LCN2 had an 
effect on hPSCs. 
        Due to the fact that LCN2 is involved in iron transport, we asked whether LCN2 
could also mediate iron regulation in hPSCs. Iron is an essential mediator of cellular 
growth, proliferation and metabolism. It is involved in oxygen transport, DNA 
synthesis and in the activity of many enzymes serving as an essential cofactor in 
many biological processes (Beard, 2001; Cherayil, 2011; Yang et al., 2002). Due to 
this, iron transport, storage and excretion are tightly regulated as either diminished 
or excess iron could result in malignancies. Ferritin (FTH1) is an iron-storage 
molecule that can store up to 4,500 iron atoms (De Domenico et al., 2008). It is a 
multimer comprised of heavy and light subunits with the heavy subunit containing 
ferroxidase activity. Ferritin is thus able to oxidize ferrous (Fe2+) to ferric (Fe3+) iron 
within its shell and store ferric iron. Along with other iron storage and transport 
molecules, ferritin is post-transcriptionally regulated by iron-regulatory proteins 
(IRPs) (De Domenico et al., 2008). During iron deficiency, IRPs bind iron responsive 
elements (IREs) that are present in ferritin mRNA and prevent the translation of the 
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mRNA (Rouault, 2006). In iron-replete conditions, IRPs don’t bind IREs resulting in 
the unhindered mRNA translation of ferritin. Thus, ferritin mRNA expression levels 
have been and are continued to be used as indicators of changes in iron levels in 
cells. Therefore, we examined if treating hPSCs with different doses of rhLCN2 at 
different time points led to changes in ferritin expression. Treatment with 50, 100 and 
500 ng/mL rhLCN2 induced the expression of ferritin mRNA at 15, 30 and 60 
minutes (Figure 17b). Moreover, the highest induction was observed after 60 
minutes of treatment with 100 ng/mL rhLCN2 when ferritin levels were upregulated 
three-fold. These results indicated LCN2’s ability to affect an iron responsive 
molecule and potentially mediate the regulation of iron levels inside hPSCs. 
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Figure 17. rhLCN2 induces the expression of IL-6 and the iron-responsive 
molecule ferritin (FTH1) in hPSCs. (A) 50, 100 or 500 ng/mL of rhLCN2 was 
ectopically added to hPSCs for either 15, 30 or 60 minutes. Treatment with rhLCN2 
led to the increased expression of IL-6 (B) rhLCN2 treatment similarly led to the 
increased mRNA expression of FTH1 indicating LCN2’s potential to regulate iron 
levels in hPSCs. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (student t-test) 
Knockdown of the LCN2-specific receptor SLC22A17  
       After determining that LCN2 induces inflammatory and iron-responsive gene 
expression changes in hPSCs, we then studied if these observations could be 
potentially mediated by the LCN2 receptor SLC22A17.  In order to do this, we 
performed cellular shRNA-mediated knockdown of SLC22A17. We purchased 
several shSLC22A17 bacterial glycerol stocks from a commercial source, purified 
shSLC22A17 plasmids and packaged them into lentiviral particles as detailed in the 
methods chapter 2. HPSCs were then transfected with these viruses and selected 
with puromycin to develop stable cell lines. Subsequently, we assessed the 
SLC22A17 mRNA levels in these hPSCs cells (Figure 18a). Results indicated that 
our vector control, HPSC PGZIP, expressed similar SLC22A17 mRNA levels as our 
untreated hPSCs. Further, one of our constructs, shSLC 4, expressed significantly 
reduced SLC22A17 mRNA levels. Over seventy-three percent SLC22A17 mRNA 
knockdown was achieved with this plasmid. Protein analysis of our vector control 
and shSLC22A17 4 cell lines confirmed knockdown of the SLC22A17 protein 
(Figure 18b).  
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 Figure 18. SLC22A17 knockdown in hPSCs. (A) Different shSLC22A17 plasmids 
were assessed for their ability to knockdown SLC22A17 mRNA expression. shSLC 4 
showed over seventy-three percent knockdown of SLC22A17 mRNA (B) SLC22A17 
knockdown was confirmed at the protein level in hPSCs. ***p<0.001 (student t-test) 
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LCN2 induces a receptor-mediated expression of pro-inflammatory molecules 
        After confirming the knockdown of SLC22A17, we examined the effects of 
rhLCN2 in hPSCs with or without the SLC22A17 receptor. Given our results 
examining rhLCN2 treatment at different doses, we decided to continue further 
experiments using either 100 or 500 ng/mL rhLCN2. Moreover, we extended the 
treatment times to examine effects several hours to two days after rhLCN2 
treatment. In addition to looking at IL-6, we assessed the expression of other 
cytokines including the monocyte chemotactic protein 1 (MCP1), Interleukin-8 (IL-8) 
and Interleukin 1B (IL-1B) as they have also been shown to be secreted by hPSCs.   
        As mentioned earlier, we first decided to examine IL-6 expression as it is a pro-
inflammatory cytokine that is implicated in the progression of PDAC. Similar to our 
previous results, we observed that IL-6 mRNA expression was significantly 
upregulated after one hour of treatment with 100 ng/mL rhLCN2 (Figure 19a). 
Chiefly, this experiment indicated that IL-6 expression was further upregulated after 
24 and 48 hours of rhLCN2 treatment. Upon knocking down the expression of 
SLC22A17, LCN2’s positive effect on IL-6 expression was abrogated. This 
significant reduction in LCN2’s effects was true at all time points indicating that 
SLC22A17 may mediate IL-6 upregulation by LCN2. 
        MCP-1 is a chemokine that is synthesized and secreted by many cell types 
including fibroblast, monocytes and macrophages among others (Schall, 1991). It is 
a potent recruiter of macrophages, memory T-cells and dendritic cells to sites of 
inflammation (Takaya et al., 2000).  Further, MCP-1 expression has been implicated 
in the recruitment of these inflammatory cells in breast, ovarian, prostate and 
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pancreatic cancers (Lazar et al., 2010). MCP-1 is expressed by PDAC cell lines as 
well as by hPSCs. One study has previously indicated that high serum levels of 
MCP-1 are more likely to occur in patients with PDAC (Sullivan et al., 2011). Given 
the implications of MCP-1 involvement in inflammation and PDAC, we examined the 
effects of rhLCN2 treatment on MCP-1 expression by hPSCs. Significant 
upregulation of MCP-1 mRNA expression was observed after 24 and 48 hours of 
rhLCN2 treatment (Figure 19b). This upregulation was diminished in hPSCs with 
SLC22A17 knockdown. These results indicate that both LCN2 and SLC22A17 may 
play a role in MCP-1 expression leading to the infiltration of immune cells at sites of 
pancreatic injury.  
        IL-8 is a pro-inflammatory activator and chemoattractant for neutrophils (Andoh 
et al., 2000a; Takaya et al., 2000).  It has been found to be secreted by several 
PDAC cell lines and further upregulated by other pro-inflammatory molecules 
(Andoh et al., 2000a; Andoh et al., 2000b). In addition, IL-8 has been shown to be a 
potential activator of hPSCs which in turn leads to sustained secretion of IL-8 and 
other cytokines (Omary et al., 2007). In PDAC, IL-8 has been shown to be 
upregulated compared to in benign patients (Frick et al., 2008; Hussain et al., 2010). 
Moreover, it has been proposed that IL-8 can serve as a serum diagnostic and 
prognostic marker for PDAC (Blogowski et al., 2014; Chen et al., 2012; Shaw et al., 
2014). For these reasons, we decided to analyze the changes in IL-8 expression 
upon treating hPSCs with rhLCN2. Our results showed that rhLCN2 does not affect 
IL-8 expression up until after 24 or 48 hours of treatment (Figure 19c). IL-8 mRNA 
was upregulated upwards to three-fold at these two time points compared to 
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untreated cells. Again, SLC22A17 knockdown was able to alleviate the expression of 
this chemokine upon LCN2 treatment.  
      The last inflammatory cytokine we studied was Interleukin 1B (IL-1B). As with IL-
6 and IL-8, IL-1B has been shown capable of inducing the activation of hPSCs and 
to be secreted by the same cells (Omary et al., 2007). Moreover, IL-1B can induce 
the expression of other cytokines including IL-6, IL-8 and MCP-1 making IL-1B a 
potent pro-inflammatory molecule (Takaya et al., 2000). In PDAC, IL-1B is implicated 
in tumor progression and has been associated with a poor histopathologic response 
to neoadjuvant therapy (Delitto et al., 2015). Likewise, IL-1B has been studied and 
proposed as a potential serum biomarker for discriminating between PDAC patients 
and benign individuals (Shaw et al., 2014). Therefore, it was of no surprise to find 
that rhLCN2 also significantly induced the expression of IL-1B after 24 and 48 hours 
of treatment (Figure 19d). Accordingly, this induction was shown to be mediated by 
SLC22A17 expression. The fact that LCN2 induces the expression of potent pro-
inflammatory cytokines and chemokines in activated hPSCs indicates that LCN2 
promotes an inflammatory response in the pancreas microenvironment.   
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Figure 19. rhLCN2 induces a SLC22A17-mediated pro-inflammatory cytokine 
response in hPSCs. 100 ng/mL of rhLCN2 was ectopically added to hPSCs with or 
without SLC22A17 knockdown at several different time points. The resulting effect 
on the mRNA expression of (A) IL-6 (B) MCP-1 (C) IL-8 and (D) IL-1B was 
examined. rhLC2 induces a significant upregulation of all molecules at the later time 
73 
 
points of 24 and 48 hours after treatment. This effect is diminished upon knocking 
down SLC22A17.  *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (student t-test) 
LCN2 induces a receptor-mediated expression of Matrix Metalloproteinases  
        In addition to producing pro-inflammatory cytokines and chemokines, activated 
hPSCs also secrete molecules that can alter the physical structure of the ECM. 
Matrix metalloproteinases (MMPs) are enzymes that play an important role in tissue 
remodeling by degrading the ECM and basement membrane components (Sorsa et 
al., 2004). This family of over twenty enzymes can be divided into six groups based 
on their substrate specificity, sequence similarities and organization of their domains 
(Visse and Nagase, 2003).They are secreted by various cell types including 
fibroblasts, endothelial cells, macrophages, neutrophils and lymphocytes (Verma 
and Hansch, 2007). Consequently, these molecules are involved in a milieu of 
physiological and pathological processes including immune response, inflammation, 
wound healing and in cancer (Verma and Hansch, 2007). Several MMPs are 
upregulated and have been correlated with the invasive and metastatic potential of 
several cancers (Foda and Zucker, 2001; Rundhaug, 2003). MMP-1, MMP-3 and 
MMP-9 have all been implicated in tumor progression (Foda and Zucker, 2001). 
Moreover, the expression of these three MMPs has been shown to correlate with the 
degree of desmoplasia, metastases and survival in pancreatic cancer (Bloomston et 
al., 2002). 
        MMP-1 falls under the collagenase group of MMPs as it is able to degrade 
collagens I, II and III among other proteins (Visse and Nagase, 2003). It has been 
specifically associated with aiding cell migration and proliferation. In pancreatic 
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cancer, MMP-1 is expressed in tumor cells as well as in stromal fibroblasts. 
Moreover, its expression in primary tumors has been correlated with poor prognosis 
(Ito et al., 1999). Thus, due to its role in regulating the structure of the tumor 
microenvironment and the fact that it is secreted by hPSCs, we examined if whether 
LCN2 regulated the expression of MMP-1 in hPSCs. We treated hPSCs with 100 
ng/mL rhLCN2 for either 24 or 48 hours (Figure 20a). After 24 hours of treatment, 
LCN2 upregulated MMP-1 expression over three-fold compared to untreated cells. A 
significant upregulation was also seen at 48 hours but knockdown of the LCN2-
specific receptor abrogated these changes at both time points.  
        MMP-3 is a stromelysin capable of degrading multiple molecules including 
collages II, III, IV, IX, X, fibronectin, laminin and elastin among others (Visse and 
Nagase, 2003). Of note, MMP-3 plays a role in the generation of other fully active 
MMPs including MMP-1, MMP-7 and MMP-9 (Bini et al., 1996). Accordingly, MMP-3  
is associated with tumor invasion (Moilanen et al., 2003). In PDAC, tumor cell 
expression of MMP-3 has been shown to be a prognostic factor for poor survival and 
promote PDAC (Mehner et al., 2014; Mehner et al., 2015). In fact, hPSCs secreting 
higher levels of MMP-3 were found to promote tumor growth and invasion (Ikenaga 
et al., 2010). We also investigated if LCN2 could promote the expression of MMP-3 
in hPSCs. Our results indicated that rhLCN2 treatment can in fact lead to the 
elevated expression of MMP-3 (Figure 20b). This was observed at both at 24 and 
48 hours after treatment with the more significant induction occurring at 24 hours 
after treatment. SLC22A17 also seemed to mediate MMP-3 upregulation as its 
knockdown reverted MMP-3 expression back to those of untreated cells. 
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        MMP-9 is a gelatinase that can degrade gelatins and collagens IV and V 
among other molecules (Visse and Nagase, 2003). It has been shown to be 
expressed by tumors cell and by stromal immune cells (Thomas et al., 1999). 
Moreover, MMP9 can be found in a complex with LCN2 in the extracellular space 
where macrophages and neutrophils are thought to be the sources of this complex 
(Chakraborty et al., 2012). This then leads to the stabilization of MMP-9 by 
preventing its degradation and potentially a more invasive tumor (Candido et al., 
2016). In PDAC, MMP-9 is secreted by both tumor cells and hPSCs (Lunardi et al., 
2014). Additionally, it has been found to correlate with the degree of desmoplasia 
and nodal status (Bloomston et al., 2002). Thus, the interaction between LCN2 and 
MMP9 appears to contribute to a more pro-tumorigenic stroma. Correspondingly, we 
assessed if LCN2 affected MMP-9 expression in hPSCs. Upon 24 and 48 hours of 
treatment, rhLCN2 induced a significant upregulation of MMP-9 (Figure 20c). This 
also was mediated by the presence of SLC22A17.  
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Figure 20. rhLCN2 induces the SLC22A17-mediated expression of matrix 
metalloproteinases in hPSCs. 100 ng/mL of rhLCN2 was ectopically added to 
hPSCs with or without SLC22A17 knockdown at 24 and 48 hours. The resulting 
effect on the mRNA expression of (A) MMP1 (B) MMP3 and (C) MMP9 was 
examined. rhLC2 induced a significant upregulation of all MMPs which diminished 
upon knocking down SLC22A17.  *p<0.05, **p<0.01, ***p<0.001 (student t-test) 
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LCN2 induces further activation of hPSCs 
        Pancreatic stellate cells are quiescent components of the pancreas until 
pancreatic injury results in their activation. Growth factors, cytokines, and 
transcription factors have been found to activate hPSCs (Omary et al., 2007). This 
activation results in morphological changes and expression of certain molecules that 
distinguish them from their quiescent state. Upon activation, hPSCs gain the 
expression of alpha smooth muscle actin (α-SMA), a molecule involved in cell 
motility and structure. It is these activated cells that secret the myriad of molecules 
that allow them to become a source of fibrosis in PDAC. Therefore, since we 
observed in this study that LCN2 induces the expression of pro-inflammatory and 
ECM components known to be secreted by hPSCs, we examined if LCN2 could also 
affect the expression of α-SMA. For these studies we utlilized hPSCs that were 
immortalized to allow continuous in vitro growth.  Stellate cells are somewhat 
activated in culture.   Nonetheless, ectopic rhLCN2 led to a significant upregulation 
of α-SMA at 24 and 48 hours after treatment (Figure 21). α-SMA expression 
reverted to normal levels in cells with SLC22A17 knockdown. Thus, LCN2 could be 
added to the list of molecules that can lead to hPSC activation.  
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Figure 21. rhLCN2 induces the SLC22A17-mediated expression of α-SMA, the 
marker of active hPSC. 100 ng/mL of rhLCN2 was ectopically added to hPSCs with 
or without SLC22A17 knockdown at 24 and 48 hours. α-SMA was found to be 
upregulated upon treatment in a receptor-mediated fashion indicating LCN2’s ability 
to further incite the activation of these cells. ***p<0.001 (student t-test) 
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LCN2 mediates the secretion of potent pro-inflammatory cytokines in hPSCs 
        Our results have indicated that LCN2 has the potential to promote hPSCs to 
synthesize pro-inflammatory cytokines, chemokines and MMPs. All these molecules 
have been implicated in inflammation and in cancer. More specifically, they have 
been found to be able to promote an inflammatory response and the remodeling of 
the stroma to create a more favorable tumor microenvironment for tumor growth and 
metastasis. Therefore, we decided to assess if any of these molecules were 
secreted by hPSCs upon treatment with rhLCN2. We employed the use of a human 
cytokine array panel to detect cytokine differences between LCN2 treated and 
untreated cells. 
     After treating hPSCs with 500 ng/mL rhLCN2 for 48 hours, we collected cell 
supernatants, concentrated the samples ten-fold using centrifugal filter units and 
assessed cytokine levels using a cytokine array kit. Briefly, cell supernatants were 
incubated with a cocktail of biotinylated detection antibodies and a cytokine array 
panel membrane, then incubated with Strepavidin-HRP and finally subjected to X-
ray film for chemiluminescence detection. The resulting positive signals on the 
developed film were analyzed using a protein array analyzer tool set for the ImageJ 
software. Here, the average pixel density was analyzed for each signal, background 
signal was subtracted and resulting pixel densities were graphed to determine 
relative changes in cytokine expression. Upon developing the nitrocellulose 
membranes containing different capture cytokine antibodies, we noticed obvious 
differences between LCN2 treated and untreated cells. In the membrane incubated 
with treated cell supernatants we observed the notable appearance of three different 
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sets of dots as highlighted in Figure 22a. According to the kit array coordinates, we 
quickly identified these sets of dots to belong to the complement component 5/5a, 
IL-6 and the stromal cell-derived factor 1 (SDF-1). 
        The complement system is a key part of the innate immunity. C5 is a 
component protein member of the complement system that can be produced 
through both the classical and alternative pathways. C5a is a pro-inflammatory 
fragment that is cleaved from C5 via the C5 convertase (Morgan and Harris, 2015). 
It is a potent chemoattractant for neutrophils and macrophages (Darling et al., 2015; 
Ward, 2004).  Thus, C5a has been implicated in many diseases including cancer 
due to its powerful inflammatory effect. Moreover, high C5a levels have shown to 
stimulate tumor progression, invasion and migration (Gunn et al., 2012; Kim et al., 
2005; Nitta et al., 2013). In addition, C5a has been shown to be able to activate 
PSCs and high C5a levels have been found to be significantly elevated in the serum 
of PDAC patients compared to healthy individuals (Sendler et al., 2015; Tonack et 
al., 2013). Quantification of the mean pixel density clearly indicated a significant 
upregulation in C5a secretion by hPSCs upon LCN2 treatment (Figure 22b). This 
further corroborates LCN2’s potential role as an important pro-inflammatory 
molecule in the PDAC tumor microenvironment.  
        In addition to C5a, the mean pixel density analysis confirmed the significant 
expression of IL-6, SDF-1, IL-8 and ICAM-1 after LCN2 treatment. This confirms our 
previous results in which we saw induction of IL-6 mRNA in hPSCs due to LCN2. 
SDF-1 is an efficient chemoattractant of lymphocytes and monocytes (Bleul et al., 
1996). It has been shown to be secreted by fibroblasts resulting in MMP expression 
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and increased tumor invasion potential (Orimo et al., 2005; Tjomsland et al., 2011). 
Moreover, hPSCs have been shown to produce SDF-1 which may mediate paracrine 
functions on PDAC cells (Duner et al., 2010; Mace et al., 2013). Thus the secretion 
of these three factors suggest that LCN2 promotes hPSCs to produce potent 
inflammatory cell chemoattractants leading to a significant remodeling of the tumor 
stroma.  
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Figure 22. rhLCN2 induces the secretion of pro-inflammatory molecules in 
hPSC. A human cytokine array panel was used to detect differences in cytokines in 
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cell supernatants after treating hPSCs with 500 ng/mL of rhLCN2 for 48 hours. (A) 
The cytokine array membrane panel clearly indicates a difference in the secretion of 
cytokines after rhLCN2 treatment belonging to Complement component C5a, IL-6 
and stromal cell-derived factor 1 (SDF-1), IL-8 and ICAM-1 (B) The mean pixel 
density quantification indicated a significant upregulation in the secretion of these 
molecules. *p<0.01, ***p<0.001 (student t-test) 
LCN2 induces a receptor-mediated expression of Complement component C5a 
and its receptor C5aR1 in hPSCs 
        Because C5a is such a potent mediator of inflammation and immune cell 
infiltration to areas of injury, we investigated if its expression in hPSCs could also be 
mediated by SLC22A17 in addition to by LCN2. After treatment with 100 ng/mL 
rhLCN2 for 24 and 48 hours, we observed a significant upregulation of C5/C5a 
mRNA confirming our human cytokine array results (Figure 23a). However, we saw 
that SLC22A17 knockdown mitigated this induction indicating its role in LCN2 
mediated C5a expression. Additionally, we assessed the effect of LCN2 on the 
expression of the C5a receptor C5aR1. This receptor is critical in mediating several 
downstream signaling cascades that are impacted by secreted C5a including the 
MAPK pathway in neutrophils (Ward, 2004). Moreover, C5aR1 expression was 
found on the cancerous epithelium of the pancreas compared to normal tissue (Nitta 
et al., 2013). We found that C5aR1 mRNA expression in hPSCs was induced by 
LCN2 and that this was mediated by SLC22A17 expression (Figure 23b). 
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 Figure 23. rhLCN2 induces a SLC22A17-mediated expression of Complement 
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component C5a and its receptor C5aR1 in hPSCs. hPSCs with or without 
SLC22A17 were treated with 100 ng/mL of rhLCN2 for 24 or 48 hours. (A-B) The 
mRNA expression of C5a and C5aR1 were upregulated by rhLCN2 but diminished 
upon SLC22A17 knockdown. *p<0.01, **p<0.01, ****p<0.0001 (student t-test) 
LCN2 induces a receptor-mediated increase in iron and iron-responsive genes 
in hPSCs 
        LCN2’s main biological function involves iron trafficking into and out of cells. 
SLC22A17 was found to mediate iron-uptake and iron-depletion by LCN2 in HeLa 
cells (Devireddy et al., 2005). The ability of LCN2 to regulate iron levels in cells has 
become an active area of research as the tight regulation of iron is crucial to many 
cell biological functions. The labile iron (Fe2+) pool in cells can modulate energy 
generation, DNA synthesis and the expression of the many iron responsive genes. 
Malignant cells have been previously shown to contain higher amounts of labile iron 
(Torti and Torti, 2011, 2013).  
        Given LCN2’s role in iron regulation, we examined if LCN2 could induce iron 
level changes in hPSCs. An iron colorimetric assay was used to analyze iron level 
changes after LCN2 treatment. Upon treatment with 100 ng/mL rhLCN2 for 24 and 
48 hours, we observed an upregulation of ferrous iron (Fe2+) in hPSCs (Figure 24a). 
This was shown to be regulated by SLC22A17 expression. Further, we examined 
the expression of iron responsive molecules as a read out of iron level changes. 
Ferritin (FTH1) is an iron storage molecule that is upregulated in the presence of 
increased iron. Indeed, we confirmed that iron levels were higher in hPSCs after 
LCN2 treatment as FTH1 mRNA levels increased accordingly (Figure 24b). 
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Likewise, the mRNA levels of the iron exporter ferroportin (SLC40A1) are 
upregulated in response to increased iron. We confirmed this to be true upon LCN2 
treatment (Figure 24c). The transferrin receptor (TFR1) aids in the endocytosis of 
the iron-binding molecule transferrin. TFR1 expression has been shown to decrease 
upon increased iron levels in cells in order to preserve iron homeostasis. We 
however, observed that TFR1 mRNA levels were upregulated upon LCN2 treatment 
(Figure 24d). TFR1 levels have been actually shown to be differentially upregulated 
in PDAC (Ryschich et al., 2004). Thus, hPSCs may be a source the TFR1 
upregulation observed in PDAC. These results show that LCN2 can regulate iron 
levels in hPSCs via its receptor. 
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 Figure 24. rhLCN2 induces a SLC22A17-mediated upregulation of iron in 
hPSCs. hPSCs with or without SLC22A17 were treated with 100 ng/mL of rhLCN2 
for 24 or 48 hours. (A) An iron colorimetric assay was used to assess changes in 
ferrous iron levels in hPSCs. LCN2 induced a receptor-mediated increase in iron in 
hPSCs. (B-D) Iron level regulation was further confirmed by examining the mRNA 
expression of iron-responsive molecules in hPSCs.  *p<0.01, **p<0.01, ****p<0.0001 
(student t-test) 
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The iron chelator Deferoxamine diminishes the effects of LCN2 on hPSCs  
        Deferoxamine (DFO) is a small molecule that binds iron with high affinity. It has 
been previously used to treat patients suffering from iron overload as well as cancer 
patients (Torti and Torti, 2013). Since LCN2 regulates iron levels in hPSCs, we 
asked whether iron could be responsible for inducing the pro-inflammatory changes 
we have shown. In order to study this, we treated hPSCs with 500 ng/mL rhLCN2 
with or without 20 µM DFO. This simulated a competition assay as LCN2 would 
compete with DFO to acquire any iron available from the cell culture media. Our 
results indicated that the addition of both LCN2 and DFO to hPSCs diminished the 
stimulation MCP-1, IL-1B and MMP-1 compared to just LCN2 alone (Figure 25 A-
C). Moreover, we confirmed that the addition of DFO reduced the expression of the 
iron responsive molecules FTH1 and ferroportin indicative of a decrease in iron 
levels inside hPSCs (Figure 25 D-E). Thus, our results suggest that iron is at least 
partially responsible for promoting an LCN2-mediated pro-inflammatory phenotype in 
hPSCs. 
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Figure 25. The iron chelator DFO diminishes the effects of LCN2 on hPSCs. 
hPSCs were treated with 500 ng/mL rhLCN2  with and without 20 µM DFO (A-C) 
DFO competition indicated that iron mediated the upregulation of MCP1, IL-1B and 
MMP1 by LCN2 (D-E) DFO decreased iron levels inside hPSCs as determined by a 
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decrease in FTH1 and ferroportin mRNA expression.  *p<0.01, **p<0.01, 
****p<0.0001 (student t-test) 
LCN2 induces SLC22A17-mediated pro-inflammatory response in another 
hPSC line 
        In order to confirm that LCN2 indeed affects hPSCs in a receptor mediated 
fashion, we transiently knockdown SLC22A17 in another hPSC line using siRNA. 
Using a non-targeting scrambled siControl RNA, we confirmed the significant mRNA 
decrease in SLC22A17 expression (Figure 26 A). After confirming this knockdown, 
we then treated these cells with 500 ng/mL rhLCN2 24 hours after transfection for a 
period of 24 hours. We confirmed that the expression of IL-6, C5a, MMP-1 and 
FTH1 increased after LCN2 treatment in cells transfected with siControl (Figure 26 
B). As with our stable knockdown cell line, we observed that transient SLC22A17 
knockdown significantly diminished the effects of LCN2. Thus, we confirmed that 
LCN2 induces a receptor-mediated production of pro-inflammatory mediators and an 
iron responsive molecule in another hPSC line.    
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Figure 26. rhLCN2 induces a SLC22A17 mediated pro-inflammatory response 
in another hPSC line. (A) SLC22A17 was transiently knockdown in another hPSC 
line using siRNA. (B) hPSCs were treated with 500 ng/mL rhLCN2  with and without 
SLC22A17. LCN2 treatment induced the upregulation of IL-6, C5a, MMP1 and FTH1 
in receptor-mediated fashion. **p<0.01, ***p<0.001, ****p<0.0001 (student t-test) 
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Chapter 5: 
Discussion   
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        Pancreatic ductal adenocarcinoma is a deadly disease projected to become the 
second leading cause of cancer related deaths in the next fifteen years (Rahib et al., 
2014). The dismal prognosis for PDAC has been attributed to the fact that the 
disease has spread at the time of diagnosis. Furthermore, over fifty-three percent of 
patients have advanced PDAC when diagnosed. Due to this, only a small 
percentage of patients are eligible for surgical tumor resection leaving chemotherapy 
as the only treatment option for the majority of patients. Low chemotherapy drug 
efficiency has been suggested to be caused by the high amount of tumor stroma 
content and low vasculature present in this solid tumor (Fokas et al., 2015). In many 
cases, the strong desmoplastic reaction observed in PDAC accounts for the 
majority, 50-90%, of the tumor volume. Thus, modifying the stroma to allow for 
increased drug penetrability has been an active area of research.  
        Important components of the PDAC stroma include ECM proteins, cytokines, 
growth factors, MMPs, hPSCs and inflammatory cells. These components have 
been shown to appear early on during pre-invasive lesions, pancreatitis and remain 
present through the development of invasive PDAC. It has been previously shown 
that an important crosstalk between tumor cells and stromal components can 
mediate tumor growth and progression. Chiefly, factors secreted by tumor cells can 
activate hPSCs resulting in the deposition of ECM proteins and the secretion of pro-
inflammatory mediators that recruit immune cells to areas of injury. LCN2 is a 
molecule that is differentially upregulated in PDAC compared to in pancreatitis or a 
normal pancreas (Moniaux et al., 2008). Prior studies have revealed its correlation 
with malignant disease, its regulation by pro-inflammatory mediators and its ability to 
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induce inflammatory cell recruitment (Chakraborty et al., 2012). Attempts to 
investigate its biological function in PDAC have unfortunately led to conflicting 
results. Given that LCN2’s potential use as a PDAC marker has been suggested by 
many, it is essential to clarify its role in PDAC and the microenvironment. In this 
study, we examined the effect of LCN2 depletion on in vivo tumor growth and 
investigated a potential mechanism by which LCN2 may promote the establishment 
of a pro-tumorigenic microenvironment in PDAC. 
Role of LCN2 in tumor growth, ECM remodeling and survival 
        We made use of a syngeneic orthotopic mouse model of PDAC to preserve the 
important tumor-host interactions. Aggressive tumor cells derived from a KPC 
mouse model of PDAC were injected directly into the pancreas of mice with 
endogenous or whole-body depleted LCN2 expression. Within this experimental 
model, we examined if re-introduction of LCN2 expression via KPC cells specifically 
in the pancreas of LCN2 null mice would affect tumor growth. Murine KPC cells have 
been used by many and shown to be able to result in tumor growth in syngeneic 
orthotopic studies (Ma et al., 2013; Olive et al., 2009). Starting from the second 
week after surgery, we visually observed a decrease in tumor growth in LCN2 null 
animals. At three weeks, it became evident that whole-body LCN2 depletion 
significantly delayed tumor growth. Previous studies have shown LCN2’s potential to 
promote cell and tumor growth (Fernandez et al., 2005; Mishra et al., 2004). 
However, modification of LCN2 expression in PDAC cells has shown to have no 
effect on cell growth rate in vitro (Leung et al., 2012; Tong et al., 2008). Upon 
histological examination, we observed that pancreatic tissue from LCN2 null animals 
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exhibited minimal staining of the cell proliferation maker Ki67. In fact, even in LCN2 
animals that did develop tumors at a later time (86 days), Ki67 staining was 
diminished in comparison to tumors from LCN2(+/+) animals (37 days). Given that 
LCN2 expression was not modified in KPC cells themselves, our results suggest that 
other factors, including changes in the tumor microenvironment due the systemic 
depletion of LCN2, may have led to decreased tumor cell growth.  
        The PDAC stroma, a hallmark of this solid tumor,  is rich in collagen type I and 
III content (Hezel et al., 2006). Increased collagen expression in human tissue has 
been previously associated with a poor prognosis and increased metastasis 
(Ramaswamy et al., 2003). Collagenous matrices have been shown to alter the 
morphology, growth, migration and adhesion of normal cells (Kleinman et al., 1981). 
Moreover, alterations in collagens I and III content has been shown to increase 
tumor cell proliferation, migration and survival (Li et al., 2014). The tumors formed in 
LCN2(+/+) animals demonstrated the development of extensive collagen networks 
compared to LCN2 null animals with or without tumor. PicroSirius red staining 
indicated specifically the accumulation of collagens I and III in LCN2(+/+) animals. 
Studies in PDAC cells have shown that collagen I and III enhance tumor cell 
proliferation, motility and reduce drug penetration (Miyamoto et al., 2004; Shields et 
al., 2011). Thus, we propose that the development of extensive collagen networks in 
LCN2(+/+) mice could be responsible increased tumor cell growth observed in these 
mice as shown by Ki67 staining.  
        We also observed the activation of PSCs in LCN2(+/+) animals as shown by 
increased α-SMA staining. It has been established that PSCs are key regulators of 
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ECM deposition and cytokine/chemokine secretion upon inflammatory stimulus. 
Further analysis of the pancreas of these animals revealed a significant upregulation 
in the mRNA expression of IL-6, IL-1β, MCP-1 and MMP-9.  In PDAC, IL-6 has been 
shown to be required for the maintenance and progression of pancreatic pre-
invasive lesions (Zhang et al., 2013). This group also reported that IL-6 null animals 
were no longer able to maintain active fibroblasts and IL-1β expression was also 
diminished. IL-6 and IL-1β are activators of PSCs and are themselves produced by 
PSCs. Thus, the significantly lower levels of these two cytokines observed in LCN2 
null animals may be due to the diminished amount of activated PSCs.  
        In addition to crosstalk between tumor and PSCs, stromal mediators are also 
able to regulate each other (Feig et al., 2012). For instance, IL-1β is a major 
activator of IL-6 expression and it has been proposed to also regulate the expression 
of MMP-9 (Wu et al., 2009). Moreover, increased IL-1β expression can upregulate 
the expression of MCP-1 and IL-6 can upregulate ICAM-1 and M-CSF (Chomarat et 
al., 2000). Interestingly, we observed a significant upregulation of ICAM-1 and M-
CSF in the serum of LCN2(+/+) animals. Further, the expression of all these factors 
may explain why we observed an increased infiltration of leukocytes and 
macrophages in the pancreas of LCN2(+/+) mice. IL-6, IL-1β, MCP-1, ICAM-1 and M-
CSF all serve as chemo-attractants for macrophages. In fact, previous studies have 
shown that LCN2 depletion in murine marrow cells prevented the development of 
chronic myelogenous leukemia (CML) and solid tumor, implicating LCN2 expression 
in tumor formation (Leng et al., 2008). Tumor associated macrophages are known to 
infiltrate the pancreas during the formation of pre-invasive lesion and persist 
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throughout the development of invasive carcinoma. Increased macrophage 
infiltration has been previously correlated with PDAC cell and tumor growth, drug 
resistance and survival (Pandol and Edderkaoui, 2015). In addition to affecting these 
biological functions, macrophages produce and secrete cytokines, growth factors 
and even LCN2.   
        This study’s results may help explain the significant increase in survival 
observed in LCN2 null mice. Moreover, we observed a significant decrease in the 
expression of the LCN2 specific receptor SLC22A17. High LCN2 and SLC22A17 
have been previously correlated with malignancy and poor prognosis in glioma, 
endometrial and hepatocellular cancers. Thus, depletion of LCN2, as suggested in 
this study, may contribute to decreased tumor growth and increased survival in 
PDAC.  
LCN2 activates hPSCs in a receptor and iron dependent manner 
        In an effort to understand how LCN2 depletion could lead to decreased 
malignancy, we examined the effect of LCN2 on hPSCs. Upon examination of LCN2 
expression, we discovered that hPSCs did not synthesize or secrete LCN2 like most 
PDAC cells did. Instead, we found that hPSCs expressed the receptors SLC22A17 
and LRP2 which have been shown to mediate the cellular endocytosis of LCN2. 
Moreover, hPSCs expressed the SLC22A17 receptor in significant higher quantities 
than PDAC cells. Given that LCN2 is implicated in promoting the immune response, 
we asked if LCN2’s effects could be mediated in a receptor and iron mediated 
fashion. 
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        We first achieved the knockdown of SLC22A17 in hPSCs and treated hPSCs 
with or without SLC22A17 expression with LCN2. As hypothesized, we observed 
that LCN2 induced a receptor mediated expression of the pro-inflammatory 
cytokines IL-6, IL-8, IL-1β and MCP-1. These results recapitulated the in vivo 
observations given the increased IL-6, IL-1β and MCP-1 mRNA expression in the 
pancreas of LCN2(+/+) mice. Moreover, the expression of LCN2 and increased levels 
of SLC22A17 in LCN2(+/+) animals would facilitate an increased activation of hPSCs. 
Indeed, we observed that LCN2 induced the synthesis of α-SMA in a receptor 
mediated manner indicating further activation of hPSCs. This too may help explain 
the increased α-SMA staining seen in the pancreas of LCN2(+/+) mice. Further, 
endogenous LCN2 upregulated the expression of MMP-1, MMP-3 and MMP-9. 
These molecules are involved in ECM degradation and have been previously shown 
to correlate with poor prognosis in PDAC. Additionally, because LCN2 can form a 
complex with MMP9, it is possible that LCN2 in pancreas cancer also promotes the 
stability of this MMP. Because the induction of these MMPs was diminished upon 
SLC22A17 knockdown, these results implicate this receptor in LCN2’s ability to 
promote the remodeling of the ECM.  
        LCN2 also promoted the secretion of C5a, IL-6, SDF-1, IL-8 and ICAM-1 
(Figure 26). Others have previously reported the ability of IL-6, IL-8 and ICAM-1 to 
recruit macrophages to areas of pancreatic injury. SDF-1 has been implicated in the 
development of pancreatitis, progression to PDAC and in the recruitment of 
macrophages. Just recently, a group has also reported that SDF-1 protein levels are 
significantly upregulated in PDAC compared to normal samples (Fan et al., 2016). 
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C5a expression is known to be a result of the activation of the complement system. 
It is a potent chemoattractant for neutrophils and macrophages and is expressed 
during pre-invasive lesions, pancreatitis and invasive PDAC. Recently, it was also 
reported that C5a has a role in mediating the development of fibrosis and can lead to 
PSC activation (Sendler et al., 2015) 
        Finally, we assessed if LCN2’s ability to promote the induction of all these pro-
inflammatory factors could be mediated by iron. First, we observed that endogenous 
LCN2 treatment resulted in increased ferrous iron levels in hPSCs as well as the 
modulation of the iron responsive molecules ferritin, transferrin receptor 1 and 
ferroportin. Increased labile iron pools in cells have been associated with a 
malignant phenotype. Iron can affect many cellular processes such as metabolism, 
DNA synthesis, cell growth and cell death (Evstatiev and Gasche, 2012). Thus, tight 
regulation of iron levels is essential for cell survival. Ferritin is an iron storage 
molecule whose expression is induced upon increased cellular iron levels. 
Ferroportin, and iron exporter, also responds to iron in a similar fashion. The 
expression of the transferrin receptor however, is decreased if cellular iron levels 
increase in order to maintain homeostasis. In our experiments, increased iron levels 
and increased ferritin and ferroportin were indicative of LCN2’s ability to mediate iron 
regulation in hPSCs. Moreover, this iron modulation was SLC22A17 dependent. On 
the other hand, expression of the transferrin receptor was induced in this setting. 
This is not a normal response to increased iron levels but upregulated levels of this 
receptor have been shown to be associated with a malignant phenotype in PDAC. 
Likewise, in our in vivo study we observed that the pancreas of LCN2(+/+) mice 
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expressed significantly higher mRNA levels of both ferritin and the transferrin 
receptor. These results suggest that LCN2 may mediate iron homeostasis in the 
PDAC microenvironment. To obtain a second confirmation, we treated hPSCs with 
LCN2 along with the iron chelator DFO. The results from this experiment would 
further indicate if LCN2 was responsible for increased iron levels in hPSCs. We 
observed that upon competition with DFO, ectopic LCN2 was no longer able to 
induce the expression of MCP-1, IL-1B or MMP-1. This indicated that the ability of 
LCN2 to induce these factors was not only receptor dependent but also iron 
dependent. Further, DFO competition reduced the expression of both ferritin and the 
transferrin receptor. Thus, here we report a mechanism by which LCN2 activates 
hPSCs and mediates their ability to produce pro-inflammatory factors that can alter 
the composition of the PDAC tumor microenvironment. 
Conclusion and future perspectives   
        Our results indicate the participation of LCN2 in the feed-forward loop created 
by the crosstalk between tumor cells, hPSCs and inflammatory cells (Figure 27). We 
propose a model in which malignant pancreatic cells secrete cytokines, growth 
factors and LCN2 during the formation of pre-invasive lesions which leads to the 
activation hPSCs and recruitment of macrophages to the site of injury. Activated 
hPSCs are then able to produce ECM components and inflammatory mediators, 
partly regulated by LCN2 and its receptor SLC22A17, that act in both a paracrine 
and autocrine fashion to allow for tumor cell growth, increased macrophage 
recruitment and to sustain their own activation. Macrophages are then also able to 
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secrete inflammatory mediators in addition to LCN2 to allow the persistence of 
pancreatic malignancy. 
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Figure 27. LCN2 participates in the feed-forward loop created by the crosstalk 
between tumor cells, inflammatory cells and hPSCs. LCN2 is secreted by cancer 
cells and by neutrophils and macrophages that infiltrate the PDAC stroma. LCN2 
can activate hPSCs inducing ECM deposition and the production of pro-
inflammatory mediators that can further recruit neutrophils and macrophages to the 
PDAC stroma. These mediators can also lead to sustained hPSC activation as well 
as promote cancer cell growth. Thus, LCN2 participates in a feed-forward loop that 
helps establish and maintain the PDAC stroma. 
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        Given that many have proposed the use of LCN2 as a marker of pancreatic 
malignancy, here we confirm LCN2’s role in promoting the establishment of a pro-
tumorigenic microenvironment. In addition, we have shown that LCN2 induces the 
secretion of molecules including IL-6, IL-8, ICAM-1, SDF-1, TIMP-1, IGFBP-1 and 
M-CSF that are known to be significantly and differentially upregulated in PDAC. 
Because LCN2 alone is not sufficient to detect PDAC on its own, we propose the 
use of LCN2 in a panel with some of these molecules in order to increase the 
efficiency of early PDAC detention.  
        Although we’ve reported novel findings regarding LCN2’s biological functions in 
PDAC, future studies can further examine LCN2’s role in the immune cells that 
infiltrate the PDAC stroma. Because LCN2 is also produced by inflammatory cells, it 
would be interesting to examine the effect of LCN2 deficient immune cells on tumor 
growth and survival. In order to address this, a future study could perform a bone 
marrow transplant from LCN2 null animals to animals with endogenous LCN2 
expression, after lethal irradiation to eliminate hematopoietic LCN2 production. In 
this setting, only immune cells would lack LCN2 and their response to an effect on 
tumor growth can be assessed. Additionally, because iron regulation is essential for 
survival, further studies can be performed to understand the role of LCN2 iron 
regulation in vivo. This study suggested that LCN2 depletion reduced iron levels in 
bulk pancreas. Within the scope of this study however, we did not examine which 
cells exhibited lower iron levels. It is possible that LCN2 mediated the increase of 
iron levels in tumor cells leading to their increased growth and malignancy in 
LCN2(+/+) mice. In order to confirm this, iron levels and the expression of iron-
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responsive genes in individual compartments within the pancreas can be examined. 
Nevertheless, this study elucidates and furthers the understanding of LCN2 biology 
in pancreatic cancer.  
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